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ABSTRACT 
Tyler Jay Goodwin: Treatment of Liver Metastasis via Nanoparticle Delivery of Engineered Gene 
Immunotherapies Expressed Locally and Transiently by the Liver Hepatocytes  
(Under the direction of Leaf Huang) 
Recent developments in the field of immunology, gene therapy and nanotechnology have 
brought new tactics to treat cancers and other acute diseases. Traditional strategies for cancer treatment 
relies on systemic administration of toxic small molecules. This strategy has been successful in some 
cancer types, but many cancers return or gain resistance, leaving the patient with a suppressed immune 
system due to the off-target toxicities from the chemotherapy. Therefore, more elaborate strategies are 
now being developed to avoid the off-target toxicities, while strengthening the patient’s immune 
response against these cancers. Several of these promising immune boosting therapeutics have now 
reached the clinic as antibody drugs or cancer vaccines. However, these antibody drugs are still 
showing signs of off-target toxicities due to the systemic administration. This dissertation research 
focuses on understanding the basic microenvironment of liver metastasis, the role immune signaling 
cytokines and chemokines play in the progression of this disease and recruitment of the immune cell 
populations, as well as investigate the ability to manipulate these immune signals to shift to an anti-
tumor microenvironment following nanoparticle gene delivery of a novel Trap technology. The tumor 
immune microenvironment as well as strategies to modulate the environment will be summarized and 
discussed in detail.  
The liver is the primary site of metastasis for gastrointestinal cancers and is a location highly 
susceptible to the establishment of metastasis in numerous other primary cancers, including breast, 
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lung, and pancreatic cancer. The current standard of care typically consists of primary tumor resection 
and systemic administration of potent but toxic chemotherapeutics, yielding a minimal improvement 
in the median survival rate.  CXCL12, a chemokine, is a key factor for activating the migration/survival 
pathways of CXCR4+ cancer cells and recruiting immunosuppressive cells to areas of inflammation. 
Therefore, reducing CXCL12 concentrations within the liver has the potential to decrease tumor and 
immunosuppressive cell activation/migration within the liver. However, because of off-target toxicities 
associated with systemic administration of anti-CXCL12 therapies, transient and liver-specific 
expression of a CXCL12 trap is necessary. Therefore, a lipid calcium phosphate nanoparticle optimized 
for delivering plasmid DNA, encoding an engineered CXCL12 protein trap, to the nucleus of liver 
hepatocytes was developed. This pCXCL12-trap formulation yielded transient (4 days) liver-specific 
expression, which greatly decreased the occurrence of liver metastasis in two aggressive liver 
metastasis models, including colorectal [CT-26(FL3)] and breast (4T1) cancers. Subsequent studies in 
an aggressive human colorectal liver metastasis model (HT-29) decreased the establishment of liver 
metastasis more effectively than systemic administration of the CXCL12 protein trap and to a level 
comparable to a high-dose regimen of a potent CXCR4 antagonist (AMD3100).  
Although the reduction of CXCL12 results in increase survival and reduced metastasis in 
prophylactic treatment of liver metastasis, the low population of CD8+ T-cells is a barrier which 
needs to be addressed to further improve the anti-tumor immune response. Therefore, the use of this 
LCP platform to deliver co-encapsulated phosphorylated adjuvants and peptides to increase CD8+ T-
cells within the tumor was explored. Three potent vaccine formulations were investigated for anti-
cancer efficacy. The phosphorylated adjuvants, CpG, 2’3’cGAMP, and 5’pppdsRNA were co-
encapsulated with a model phosphorylated tumor specific peptide antigen (p-AH1-A5). The anti-
cancer efficacy of these adjuvants was assessed using an orthotopic colorectal liver metastasis model 
based on highly aggressive and metastatic CT-26 FL3 cells implanted into the cecum wall. The 
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results clearly indicate that the RIG-1 ligand, 5’pppdsRNA, co-encapsulated with the p-AH1-A5 
peptide antigen greatly reduced the growth rate of the primary colon cancer as well as arrested the 
establishment of liver metastasis in comparison to the other adjuvant formulations and unvaccinated 
controls. Further evaluation of the immune cell populations within the primary tumor confirms the 
ability of the 5’pppdsRNA adjuvant to boost the adaptive CD8+ T-cell population, while not inciting 
increased populations of immune suppressive cell types such as T-regulatory cells or myeloid derived 
suppressor cells. The 5’pppdsRNA vaccine formulation can be a potent immunotherapy, especially 
when combined with agents that remodel the immune suppressive microenvironment of the tumor. 
Immunotherapies such as anti-PD-L1 and anti-CXCL12 are promising and potent anti-cancer 
treatments. Therefore, two strategies (gene immunotherapies and vaccine) as a combination to 
increase immunotherapy concentrations in the local tissue, allowing the therapy to simultaneously 
inhibit the accumulation of immune suppressive cells and liver metastasis were explored. The lipid 
calcium phosphate nanoparticles containing the pPD-L1 and pCXCL12 trap reduced the liver 
metastasis burden in an aggressive colorectal liver metastasis model (10 fold), ultimately prolonging 
the survival time in mice (>70%).  Furthermore, this combination therapy resolved the formation of 
immune suppressive ectopic lymphoid structures commonly associated with liver metastasis. The 
reduced immune suppressive microenvironment allowed for increased T-cell activation and 
migration into the liver following vaccination against tumor antigens (>180% increase in survival).  
Interestingly, the pPD-L1 and pCXCL12 trap showed superior efficacy in the treatment of the liver 
metastasis compared to free protein immunotherapies. This alternative strategy of delivering genes 
encoding potent immunotherapies for increased local concentrations in the liver reduces off-target 
concentrations, while increasing therapeutic efficacy was proposed. This strategy reduces the 
progression of liver metastasis as well as the formation of immune suppressive ectopic lymphoid 
structures, and should be considered as an alternative approach to supplement and support current 
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liver metastasis therapies as well as for future research interested in manipulating the 
chemokine/cytokine immune factors within the liver 
In summary, this immune modulating strategy proposed in this dissertation provides a new 
paradigm for treatment of liver metastasis. In addition, the combination of gene immunotherapies with 
anti-cancer vaccines provides a promising platform and pre-clinical results for which future studies in 
clinical trials are promising.  
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 Chapter 1:  Introduction1 
1.1 Summary1 
Gene therapy, once thought to be the future of medicine, has reached stages of exponential 
growth. Many types of disease are now being studied and treated in clinical trials through different 
gene delivery vectors. However, as promising as these ongoing treatments and clinical trials are, 
there are many more barriers and challenges that need to be addressed and understood in order to 
continue this positive growth. Our knowledge of these challenging factors such as gene uptake and 
expression need to grow to improve on existing delivery systems.  Furthermore, traditionally gene 
therapies have aimed at correcting a genetic disorder. However, throughout this chapter new potential 
targets aimed at modulating the liver and tumor microenvironment by delivering gene 
immunotherapies to the local tissue of interest will be discussed.  This chapter will provide a brief 
overview on recent advances in the field of non-viral vectors for gene therapy as well as discuss at 
length the potential targets and lipid based vectors to be used to express a variety of engineered 
immunotherapies within the liver microenvironment. In all, this chapter seeks to provide guidelines 
for optimizing nanoparticle-based gene delivery vectors as well as using these vectors to prime the 
liver microenvironment to resist cancer invasion.  
                                                   
1 This summary and introduction previously appeared as part of a book chapter in non-viral vectors 
for gene therapy. The original citation is as follows: Goodwin T, Huang L. Non-viral vectors: we 
have come a long way. Advances in genetics. 2014; 88:1-12. 
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1.2 Introduction1 
The past several decades have shown immense growth of knowledge in the ability to create 
and improve on non-viral vectors for the delivery of genetic material. This genetic material has great 
promise as a therapeutic agent against numerous aliments including genetic disorders, chronic and 
acute diseases, and cancer. Within this field of non-viral vectors, promising physical methods and 
chemical vectors for gene delivery consisting of electroporation techniques, cationic lipids, cationic 
polymers, hybrid lipid-polymers, as well as many other vectors/techniques have been developed.  An 
increased understanding of the field has catalyzed efficiency to new levels in which delivery of 
plasmid DNA or oligonucleotide into cells can be well characterized and has been yielding promising 
results in pre-clinical and clinical trials. These vectors have shown to be a promising alternative to 
viral vectors due to their safety, adaptability, and efficiency in large scale production. They have 
been shown to exhibit cell specificity through addition of targeting ligands, minimal immune 
toxicities through addition of inflammatory suppressor molecules, as well as sufficient genetic 
material release into the cytoplasm of the cell through endosomal destabilization via proton sponge 
effect or other mechanisms. However, even with these strides the field of non-viral gene therapy has 
many areas that need to be addressed, particularly in gene release, nuclear uptake, and expression, 
which are lagging viral vector capabilities.  
 Some of the most promising formulations for gene delivery are considered “hybrid” 
nanoparticles which usually consist of a polycation-DNA core with an outer-layer shell consisting of 
lipids. The two main groups are lipid-polycation(Protamine)-DNA (LPD) nanoparticles and 
multilayered nanoparticles, in which the multilayered nanoparticles are formulated through a layering 
technique in which cationic polymers and DNA are added sequentially. In most vectors a cationic 
polymer with the ability to condense DNA is crucial. The main challenge in selecting a cationic 
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polymer is the balance of strong yet reversible electrostatic binding which sufficiently condenses 
with the anionic DNA backbone, but will release the DNA once cellular/nuclear uptake has occurred. 
The use of cationic lipids can have higher degrees of toxicity, but also improve cellular uptake and 
endosomal release through the hexagonal fusion with the endosomal membrane. The incorporation of 
PEG with targeting ligands can also be used to decrease toxicity and improve cell-specific targeting.  
The LPD has shown to be a good gene delivery system. However, the size, and nuclear 
localization/release of DNA from the protamine has been improved on through the formulation of 
another hybrid nanoparticle consisting of a calcium phosphate core and referred to as lipid calcium 
phosphate (LCP) nanoparticles. The LCP nanoparticles takes advantage of its small size to increase 
penetration into the extracellular matrix as well as through tight blood and sinusoid vessels. 
Furthermore, the use of a nuclear localization peptide “cyclic-CR8C” allows for increase nuclear 
uptake. Following IV injection of LCP containing pLuciferase and targeted via galactose conjugated 
PEG resulted in high expression levels of luciferase in the liver of mice 2. Although hydrodynamic 
injections result in a 100 fold higher expression level than the LCP vector, it is not necessary to 
achieve these high levels to have therapeutic effects 3. Furthermore, the versatility of the LCP to 
encapsulate a range of phosphorylated molecules allows for combination therapies to be delivered via 
the same LCP vector. Therefore, the remainder of this chapter will discuss unique strategies and 
targets in which the LCP formulation will be used to deliver a variety of therapeutics ranging from 
engineered genes to cancer specific peptide antigens and adjuvants to investigate the anti-tumor 
immune response. 
1.3 Factors Promoting the Tumors Immune Suppressive Microenvironment 
The potential of a therapeutic target can only be assessed through understanding the 
environment and circumstances in which that target is produced. Additionally, the mechanism in 
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which that target promotes a certain response must be understood. The goal of this chapter aims to 
understand which factors play a critical role in the progression of the metastatic lesions in the liver. It 
has been reported that many solid tumors and metastatic lesions progress through the recruitment of 
immune suppressive cell types to the tumor niche. However, although these tumors seem to use 
similar mechanisms to establish the immune suppressive niche, the unique characteristics of the 
organ in which the tumor propagates plays a critical role.  Therefore, to target potential factors which 
promote the tumor’s immune suppressive microenvironment in the liver, the unique characteristics of 
the liver must be understood.  
The liver is a unique organ which processes numerous antigens secreted from intestinal 
bacteria. This mechanism of processing foreign pathogens which enter the body creates a tolerogenic 
liver microenvironment. Furthermore, it should be noted that the liver, like all organs, consists of a 
heterogeneous population of cell types. Each of these unique cell populations and subpopulations 
promote different responses depending on the type of activation. These populations vary from 
lymphocytes, such as innate NK T-cells and antigen presenting DCs and macrophages, to non-
lymphoid cells such as hepatocytes and endothelial cells. Furthermore, Kupffer or stellate cells are 
liver specific macrophages which contribute considerably to promoting an immunosuppressive 
microenvironment. The main immune cell populations which have been reported to establish the 
immune suppressive environment consists of Kupffer cells, pDCs, MDSCs, T-regs, and tumor 
associated M2 macrophages (TAMs). 
Kupffer cells have been shown to induce tolerance to soluble antigens encountered within the 
circulation 4. These Kupffer cells secrete immunoregulatory cytokines such as IL-10, TGF-β and IDO 
as well as upregulate membrane surface expression of the regulatory co-stimulatory molecule, B7-H1 
(PD-L1) 5. In addition to Kupffer cells, multiple subsets of hepatic DC are present within the liver. 
The plasmacytoid dendritic cells, pDCs, is the most abundant of the DCs and is located proximal to 
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the liver portal veins to process exogenous antigens. The increased frequency of pDCs in the liver 
also promotes the tolerogenic microenvironment 6 7. In other major tissues the pDCs have been 
shown to produce a robust IFN response, promoting T-cell activation. However, within the 
tolerogenic liver microenvironment the pDCs drive increased production of IL-10, enhancing the 
proliferation of immune suppressive T-regs 8.  
T-regs are a subset of CD4+ T cells that suppress effector T and NK cell activation, 
proliferation and cytokine production 9. An increase in T-regs within solid tumors is correlated with 
poor prognosis. Some promising target to reduce the accumulation and activation of T-regs within 
the liver is IL-2, CCL17, and CCL22 10 11. IL-2 is reported to be essential for the development, 
maintenance, and function of CD4+FOXP3+ T-regs. Patients that have received systemic IL-2 
therapy for the treatment of metastatic renal cell carcinoma had elevated intra-tumoral T-regs 11. T-
regs express higher levels of the chemokine receptor, CCR4. The chemokines CCL17 and CCL22 
bind to CCR4 and have been implicated in T-reg recruitment in tumors 10. Tumor cells, MDSCs, and 
activated (“M2 phenotype”) macrophages within the tumor microenvironment preferentially produce 
CCL17 and/or CCL22 12.  
Another immune suppressive cell population consist of the MDSCs. MDSCs are a 
heterogenous population containing myeloid progenitor cells and immature myeloid cells. The liver 
has recently been shown to be a preferred site for the homing and expansion of MDSCs. The 
invasion of MDSCs into the liver has been shown to increase the formation of liver metastasis 13. 
Both migration and invasion of MDSC within the liver has been shown to be promoted by increased 
concentrations of GM-CSF, the chemokine CXCL1, a granulocytic chemoattractant, stromal derived 
factor-1 (SDF-1/CXCL12), a chemoattractant, and the stem cell factor (SCF) 14-17. Recent evidence 
has shown that MDSCs inhibit the function of effector T cells and expand the T-reg populations as 
well as decrease NK cell cytotoxicity and cytokine production in liver cancer patients 18 19. 
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Furthermore, crosstalk between MDSCs and resident Kupffer cells has been shown to induce 
increased expression of PD-L1 13. 
Liver macrophages, such as the Kupffer cells, can be manipulated to promote crucial pro-
inflammatory responses (M1). However, the microenvironment strongly dictates which populations 
will be activated. Therefore, the local microenvironment can switch from M1 to an immune 
suppressive M2 populations through slight changes in the cytokine profile. Tumor-associated 
macrophages are exposed to immune suppressive signals, such as TGF-β, IL-10, VEGF and 
macrophage colony stimulating factor (M-CSF). These factors reduce M1 activation and shift the 
macrophage profile to a M2, pro-tumor population. Subsequently, M2 macrophages will produce 
high levels of IL-1 receptor antagonist, which further enables the tumor/immune microenvironment 
to establish immune evasion 20. Therefore, these factors, TGF-β, IL-10, VEGF, M-CSF, and IL-1 
may be potential therapeutic targets to be investigated for disrupting M2 differentiation. 
The chemokine-mediated recruitment of macrophages is also strongly correlated to establishment of 
immune suppressive microenvironment. The chemokine monocyte chemoattractant protein (MCP)-1 
has been strongly associated with the recruitment of M2 macrophages that facilitate tumor 
development 21. In contrast, chemokines whose expression are regulated by interferon gamma (IFN-
γ), such as CXCL9, CXCL10 and CCL5, are more closely associated with classically activated 
(“M1”) macrophages which play important roles in anti-tumor responses 21. The expression of these 
Th1/M1 associated chemokines within the patient tumor niche correlated with improved prognosis. 
However, unlike the Th1/M1 associated chemokines, CXCL5/ENA-78 and CXCL12/SDF-1 are 
associated with a Th2/M2 profile. These chemokines have been shown to mediate the recruitment of 
MDSCs into solid tumors 22. The CXCL12-CXCR4 axis is one of the representative chemokine 
signaling involved in cancer metastasis 23. In the liver, one of the most frequent sites of CRC 
metastasis, CXCL12 is secreted from the endothelial cells, stellate/Kupffer cells and α-smooth 
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muscle actin-positive myofibroblasts 24. Clinical studies have shown that CXCR4 expression 
correlates with tumor recurrence, poor survival and liver metastasis 25. Secretion of CXCL12 recruits 
not only cancer cells, but also BMDC that promote angiogenesis. Furthermore, secretion of VEGF 
was also shown to cause a pro-migratory effect on BMDC 26. Therefore it is clear that the 
CXCL12/CXCR4 axis, as well as the VEGF/VEGFR is a potential therapeutic target to reduce 
metastasis and immune suppressive cell recruitment and activation 27.  
The investigations into the critical factors promoting the immune suppressive metastatic niche 
formation within the liver has generated numerous potential therapeutic targets. The major factors 
presented in this chapter include CXCL1, CXCL5, CXCL12, CCL17, CCL22, MCP-1, VEGF, GM-
CSF, SCF, IL-2, IL-10, TGF-β, IDO, and PD-L1. These factors have been shown to contribute to 
immune suppressive cell recruitment, activation, accumulation, and T-cell deactivation within liver 
metastasis. Reducing a select few of these factors within the liver and tumor microenvironment may 
lead to anti-tumor immunity and ultimately resolve liver metastasis. 
1.4 Current Strategies to Reduce and Overcome Immune Suppressive Microenvironment 
As reported above, numerous factors play a critical role in the establishment of the livers 
immune suppressive environment. In this section, a select few of these factors which are currently 
being targeted to improve survival and reduce the immune suppressive environment in liver 
metastasis will be discussed. Therapeutic approaches that directly target/effect immune suppressive 
cells within the microenvironment have only recently emerged. The use of antibody or small 
molecule immunotherapies has proven to be effective for treatment of melanoma and metastatic 
lesions. The administration of clinically available PD-1 antibody has resulted in a dramatic 
enhancement in T-cell proliferation that was associated with reduced numbers of MDSCs and T-regs. 
This response increased survival and reduced recurrence in human patients 28. However, many off-
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target toxicities, immune-related adverse events (irAEs), have been reported following systemic 
administration of these PD-1 or other immunotherapy molecules 29. Furthermore, the efficacy against 
many solid tumors is negligible due to poor accumulation or the establishment of resistance within 
the tumor microenvironment.  
A similar approach involves the inhibition of factors essential for immune suppressive cell 
development, recruitment and/or function. It is hopeful that as the list of factors which promote the 
development of these cell types expands, new therapeutic targets and strategies for redirecting the 
differentiation of these cells away from an immunosuppressive phenotype will be developed. 
Therapeutic manipulation of immune suppressive cell recruitment within the tumor 
microenvironment is a promising approach. The ability to reduce these chemoattractant molecules 
have many favorable outcomes. Firstly, it reduces the recruitment of the immune suppressive 
monocytes, further reducing the expression of more immune suppressive cytokines and chemokines 
21. Secondly, the therapeutic modulation of chemokine profiles allows pro-inflammatory cell types 
the ability to be activated and proliferate to further overcome the immune suppressive environment. 
Mainly, this approach has the potential to shift the microenvironment from M2 to M1 population. 
The development of small molecule (plerixafor) and antibody therapies against CXCL12/CXCR4 
axis have shown promising results 30. Furthermore, several chemotherapeutic drugs such as docetaxel 
and gemcitabine reduced M2 macrophages and MDSC, respectively 31 32. These approaches, 
mentioned above, reduce the factors which recruit immune suppressive cells to the metastatic niche 
and surrounding tissue. However, in most approaches, a small molecule or antibody drug is delivered 
systemically. As previously mentioned, this strategy has been shown to result in off-target immune 
related adverse effects. Therefore, to avoid the toxicities, a more targeted approach is necessary.   
Therefore, a more targeted approach being investigate for tissue specific delivery is based on 
viral gene therapy. The goal is aimed at expressing therapeutic pro-inflammatory factors via gene 
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delivery. The most robust and targeted approach to elicit gene expression is through viral delivery 
systems. The strategy is aimed at increasing an endogenous factor within the liver via transduction. 
One such example consisted of the systemic administration of an adenovirus carrying the GM-CSF 
gene. The successful transduction into mouse liver cells resulted in a 400-fold increase in hepatic DC 
recruitment. The significant increase reversed the tolerogenic phenotype of hepatic DCs increasing 
co-stimulatory molecules, antigen processing, pro-inflammatory cytokines, and T-cell stimulation 33. 
This demonstrates one approach for immune modulation within the liver. It is dependent on 
achieving therapeutic expression of an exogenous factor within the tissue of interest. This strategy is 
a promising approach to increase expression of beneficial factors which promote a pro-inflammatory 
anti-tumor immune response. Although this study resulted in therapeutic efficacy, the use of viral 
vectors for gene delivery has some drawbacks and concerns among physicians. Particularly, 
immunity against these vectors reduces the efficacy and gene expression. 
The final approach currently being investigated is based on manipulating the hosts innate and 
adaptive immune response in such a way that the host recognizes and resists cancer progression. This 
approach doesn’t aim to reduce the immune suppressive factors, but instead boost the pro-
inflammatory response to overcome the immune suppressive microenvironment. The development 
and understanding of unique adjuvants that elicit robust immune responses through a specific 
mechanism has grown substantially. These adjuvants have seen increased use in cancer vaccine 
formulations to elicit desired immune responses against cancers. Cancer vaccines for the treatment of 
colorectal liver metastasis is promising. Several tumor associated antigens such as carcinoembryonic 
antigen (CEA), mucin 1 (MUC1), human epidermal growth factor receptor 2 (HER2) and NY-ESO-1 
have been identified 34. Many clinical trials using these antigens have reached late phase II and III 
studies 35. However, identifying vaccines which break the cancer immune tolerance, overcome the 
immune suppressive microenvironment and reduce tumor growth and liver metastasis is challenging. 
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Although cancer specific T-cell killing can be achieved, the ability to target cancer cells within 
immune suppressive niches is an obstacle which must be overcome to achieve complete remission. 
1.5 Our Approach and Strategy to Overcome These Challenges 
As mentioned above, the systemic delivery of the potent immunotherapy antibodies and small 
molecules has numerous challenges which reduce efficacy and increase off-target toxicities. 
Furthermore, the administration of viral vectors for tissue specific targeting also presents numerous 
drawbacks due to the immunity gained following administration of viral vectors. Therefore, an 
alternative approach which can overcome the mentioned obstacles will be discussed. Tissue specific 
non-viral gene therapy is one such approach which allows for the delivery of an engineered gene to 
the nucleus of liver hepatocytes. Due to the immunity gained following administration of viral 
vectors, use of a non-viral vector, lipid calcium phosphate (LCP) nanoparticle, shown to be a reliable 
liver specific gene delivery vector was utilized. This strategy could be used to delivery genes which 
code for antibody-like immunotherapies to increase concentrations in the local tissue. This approach 
allows for local (liver) and transient expression of the desired immunotherapy to simultaneously 
inhibit the accumulation of immune suppressive cells and liver metastasis.  
As mentioned above, immunotherapies such as anti-PD-L1 and anti-CXCL12 are promising and 
potent anti-cancer treatments. Therefore, the therapeutic strategy investigated in this research consists 
of using the lipid calcium phosphate nanoparticles containing the pPD-L1 and pCXCL12 trap to reduce 
PD-L1 and CXCL12 concentrations within the liver. It is hypothesized that decreased CXCL12 
concentrations will reduced immune suppressive cells within the metastatic microenvironment, while 
PD-L1 will increase T-cell activation and migration. Furthermore, due to the promising clinical 
outcomes following cancer vaccination, gene therapy approaches in combination with a model cancer 
vaccine was investigated. This investigation allows for a deeper understanding of the roles the local 
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liver immune environment, as well as the activation of the hosts systemic immune response plays in 
anti-cancer efficacy. Therefore, it is hypothesized that it is necessary to utilize a combination of 
therapies aimed at reducing the immune suppressive environment while simultaneously increasing 
CD8+ T-cell recruitment and activation.  
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 Chapter 2: Development and Investigation of Immuno-Gene Therapy, 
pCXCL12 Trap, to Prime the Liver to Resist Cancer Metastasis2 
2.1 Overview 
The liver is the primary site of metastasis for gastrointestinal cancers and is a location highly 
susceptible to the establishment of metastasis in numerous other primary cancers, including breast, 
lung, and pancreatic cancer. The current standard of care typically consists of primary tumor 
resection and systemic administration of potent but toxic chemotherapeutics, yielding a minimal 
improvement in the median survival rate.  CXCL12, a chemokine, is a key factor for activating the 
migration/survival pathways of CXCR4+ cancer cells and recruiting immunosuppressive cells to 
areas of inflammation. Therefore, reducing CXCL12 concentrations within the liver has the 
potential to decrease tumor and immunosuppressive cell activation/migration within the liver. 
However, because of off-target toxicities associated with systemic administration of anti-CXCL12 
therapies, transient and liver-specific expression of a CXCL12 trap is necessary. Therefore, a lipid 
calcium phosphate nanoparticle optimized for delivering plasmid DNA, encoding an engineered 
CXCL12 protein trap, to the nucleus of liver hepatocytes was developed. This pCXCL12-trap 
formulation yielded transient (4 days) liver-specific expression, which greatly decreased the 
                                                   
2 This chapter previously appeared as an original research article in Science Translational Medicine.  
The original citation is as follows:  Goodwin TJ, Zhou Y, Musetti SN, et al. Local and transient gene  
expression primes the liver to resist cancer metastasis. Science Translational Medicine 
2016;8(364):364ra153. 
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occurrence of liver metastasis in two aggressive liver metastasis models, including colorectal [CT-
26(FL3)] and breast (4T1) cancers. Subsequent studies in an aggressive human colorectal liver 
metastasis model (HT-29) decreased the establishment of liver metastasis more effectively than 
systemic administration of the CXCL12 protein trap and to a level comparable to a high-dose 
regimen of a potent CXCR4 antagonist (AMD3100).  
2.2 Introduction 
Colorectal cancer (CRC) is the third most prevalent cancer diagnosed worldwide and the 
third leading cause of cancer deaths. In the United States alone, approximately 143,460 patients 
were diagnosed, resulting in over 51,690 deaths in 2012 36. However, the cause of death is rarely 
due to the primary colon cancer burden itself, because local resection of cancerous colon is quite 
efficient. Unfortunately, the establishment of liver metastasis is the leading cause of death 36. At 
early stages of colorectal cancer detection, before liver metastases form, the five-year survival rate 
is approximately 90%. Regrettably, this rate drops to less than 12% once liver metastasis has been 
established. By the time of diagnosis, 20% of patients have developed liver metastasis, and 60-70% 
of patients develop metastatic lesions in the liver by time of death 37. Currently, the approved 
treatment for liver metastasis consists of liver resection and/or a combination of 5-FU with 
oxaliplatin or irinotecan with or without capecitabine. These treatments yield an overall response 
rate (ORR) of 20-30% or 40-50%, depending on regimen, and median overall survival (OS) of 12 
to 20 months 38. Although these treatments are currently the standard of care and yield improved 
efficacy over other traditional treatments, the off-target toxicities along with a median survival of 
12 to 20 months presents a less than desirable outcome. Therefore, a key strategy to improve the 
survival rate and quality of life for patients with CRC and other cancers undergoing treatment is 
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to reduce off-target toxicities. This can be achieved through tissue-specific targeting of central 
factors that directly activate liver metastasis and subsequently promote the establishment of an 
immunosuppressive tumor microenvironment.  
The relationship between the chemokine receptor CXCR4 expressed on cancer cells and 
its chemokine ligand, Stromal Derived Factor-1 (CXCL12/SDF-1), secreted by the hepatic stellate 
cells (HSC), plays a vital role in CRC and numerous other cancer liver metastasis 39. These hepatic 
stellate cells are resident perisinusoidal cells that have been shown to produce high amounts of 
endogenous CXCL12 for recruitment of immunosuppressive lymphocytes such as regulatory T 
cells (T-reg) and myeloid-derived suppressor cells (MDSCs) to areas of inflammation. In the 
presence of high amounts of CXCL12, CXCR4+ colorectal cancer cells migrate and invade along 
the CXCL12 concentration gradient. In addition, CXCR4 is expressed in a maintenance capacity 
in CRC progenitor cells to maintain stem-like characteristics 40 41. Further analyses of human 
colorectal cancer biopsies have found that a higher rate of liver metastasis correlates with high 
expression of CXCR4 39 42. Therefore, it is hypothesized that disrupting this CXCL12 gradient in 
the liver may effectively decrease the occurrence and progression of colorectal and numerous other 
CXCR4+ cancers in the liver, while drastically reducing the recruitment of immunosuppressive 
cells.  
Treatment of mice with AMD3100 (Plerixafor), a small molecule CXCR4 antagonist, has 
demonstrated the therapeutic potential of disrupting the CXCL12/CXCR4 axis resulting in the 
decreased occurrence of liver metastasis 24. Subsequently, many CXCR4 antagonists have been 
developed 43. However, the endogenous role of CXCL12 and CXCR4 in the immune system is 
vital. These treatments, which include small molecule and protein therapies, come with systemic 
off-target toxicity concerns. Furthermore, to our knowledge, no therapy targeted to CXCL12 has 
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been developed and reported to reduce the occurrence of colorectal liver metastasis. Therefore, it 
is hypothesized that an anti-cancer strategy centered on the liver-specific delivery of a gene 
encoding a small antibody-like protein to entrap CXCL12, and thereby alter the liver 
microenvironment, could be used to halt metastasis to the liver. Delivery of such genes can achieve 
reduced concentrations of CXCL12 or similar factors, priming the liver to directly reduce 
activation of the migration/invasion/survival/proliferation pathways in CXCR4+ colorectal cancer 
cells. Furthermore, this strategy has the potential to decrease the recruitment of CXCR4+ 
immunosuppressive cell types. Therefore, targeting protein factors, such as CXCL12, in the 
microenvironment of healthy tissue brings about an anti-cancer paradigm in which the metastatic 
lesions are not targeted directly. Instead, the metastasis-prone environment is primed to be 
unsuitable for the metastasis to form or progress, ultimately decreasing the establishment and 
growth of metastatic lesions.  
The development and use of a reliable syngeneic orthotopic colorectal liver metastasis 
animal model enabled investigation into the role of CXCL12 in promoting liver metastasis. This 
model, first reported by Zhang et al., involves inoculation of 2.0 x 106 CT-26(FL3) cells into the 
cecum wall to yield a high occurrence of liver metastasis (~90%) within four weeks 44. 
Subsequent establishment of a CT-26(FL3) cell line stably expressing RFP/Luciferase marker 
genes allowed the use of luciferase bioluminescent analysis to determine in vivo liver tumor 
burden. With this model, as well as the establishment of liver metastasis via hemi-splenic 
inoculation of human colorectal (HT-29) or mouse breast cancer (4T1) cell lines, the therapy’s 
ability to prime the liver microenvironment and the tumor/immune cell profile can be 
investigated. The use of syngeneic models allowed for investigation of the immune profile and 
the role of cytotoxic T lymphocytes (CTL) in reducing the progression and establishment of liver 
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metastasis. Furthermore, investigation of liver metastasis in an immunodeficient athymic mouse 
model provides insight into whether the direct disruption of the CXCR4/CXCL12 axis on the 
cancer cells’ surface is a therapeutic pathway for reducing the establishment of liver metastasis. 
These mouse models produce a reliable platform to examine whether the proposed strategy can 
be used to demonstrate in vivo anti-cancer efficacy on numerous CXCR4+ derived colorectal cell 
lines such as CT-26(FL3) and HT-29, as well as other cancers such as breast cancer (4T1) 
(Figure 2-1). It is hypothesized that the targeted (liver-specific) delivery and transient expression 
of the engineered CXCL12 trap (Trap; 28.6 kD) via a lipid calcium phosphate (LCP) non-viral 
vector can direct the liver to resist infiltrating CXCR4+ metastatic cells as well as inhibit the 
establishment of an immunosuppressive tumor microenvironment, allowing for enhanced cancer-
specific CD8+ T cell killing. 
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2.3 Materials and Methods 
2.3.1 Study design 
This was a preclinical study to assess the efficacy and safety of an engineered gene 
(pCXCL12 trap) delivered via a non-viral vector to elicit transient therapeutic protein expression 
specifically in hepatocytes. It is hypothesized that neutralization of the high amounts of 
endogenous CXCL12 produced by stellate cells in the inflamed liver would decrease the migration, 
invasion, and proliferation of colorectal liver metastases as well as shift the tumor 
microenvironment from anti- to pro-inflammatory. This hypothesis was tested through an 
established orthotopic syngeneic colorectal liver metastasis murine model as well as in two 
aggressive colorectal and breast cancer liver metastasis models. The numbers of mice used for the 
in vivo experiments are specified in the figure legends. Grouping of mice for tumor experiments 
was performed by measuring the tumor burden by bioluminescence detection, ranking the mice by 
tumor size, and distributing them equally among groups through a “snake draft” or other method 
of randomized blind selection in cases where treatment was initiated on day 0. Additional study 
design details are included in the statistical analysis section below.  
2.3.2 Materials 
1,2-Distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[succinyl(polyethyleneglycol)-
2000]-N-hydroxysuccinimide [DSPE-PEG2000–N-hydroxysuccinimide (NHS)] was purchased 
from NOF Corporation. Radioactive 177LuCl3 in 0.05 N HCl was purchased from PerkinElmer, 
Inc. and used immediately upon receipt. DSPE-PEG2000-galactose was synthesized through the 
conjugation of 10 eq. of 4-aminophenyl β-d-galactopyranoside and 1 eq. of DSPE-PEG2000-NHS 
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in PBS buffer, followed by chloroform extraction and dialysis against water using a MWCO 1000 
dialysis tube. All other lipids were purchased from Avanti Polar Lipids, Inc. Peptides (mcCR8C) 
were purchased from Elim Biopharmaceuticals, Inc.; monocyclic abbreviated to mc. Hoechst 
nucleic acid stain 3342 was purchased from ThermoFischer Scientific. Mirus LabelIT kit (Mirus 
Bio) was used for fluorescent Cy3 cDNA labeling. Luciferin was purchased from Promega 
Corporation. Plasmids encoding GFP driven by the CMV promoter were custom prepared by 
Bayou Biolabs. ELISA, IF, IHC kits, antibodies including anti-His(6×)-tag, anti-CXCL12, anti-
GR1, anti-CD11b, anti-FoxP3, anti-CD4, and anti-CD8, as well as secondary antibodies were 
purchased through Abcam. Invasion and migration assay kits were purchased through EMD 
Millipore. All other chemicals were obtained from Sigma-Aldrich and used without further 
purification. Anti-Lyt2.2 and isotype control were purchased from BioXcell. Six-week-old 
BALB/c female mice (∼18 g each) were purchased from Charles River Laboratories. Six-week-
old nude female mice (∼20 g each) were purchased from the University of North Carolina.  All 
work performed on animals was in accordance with and approved by the University of North 
Carolina Institutional Animal Care and Use Committee. 
2.3.3 CXCL12 trap gene construction 
The coding sequences of the CXCL12-binding VH and VL domains were used for assembly 
of the trap gene. The final sequence for the CXCL12 trap codes for a signaling peptide, VH domain, 
a flexible linker, VL domain, E tag, and His(6×) tag, respectively. The complete cDNA was cloned 
into pCDNA3.1 between Nhe I and Xho I sites and the accuracy was confirmed by DNA 
sequencing. The DNA sequence and vector map is available in Figure 2-2.  
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2.3.4 Expression and purification of recombinant CXCL12 trap protein 
293T cells were cultured until 70-80% confluency. To transfect the cells, 24 μg pTrap (or 
pcDNA3.1 negative control) and 40 μL Lipofectamine were added to each 10-cm plate. The serum 
concentration was reduced after transfection. 293T cells were monitored each day to ascertain their 
survival. 10 mL supernatant was harvested after 24, 48, and 72 hours, and kept at 4°C for further 
purification. The supernatants were concentrated with 10 kDa MWCO spin filters to 200 μL and 
subjected to His-Mag-Ni-Sepharose beads to purify His (6×)-tagged CXCL12 trap protein. The 
purified protein was analyzed on 10% SDS-PAGE gel with silver stain. 
2.3.5 Binding kinetics 
Bio-layer Interferometry (BLI) analyses of the affinity of recombinant CXCL12 trap 
against different chemokines were performed on a fortéBIO Octet QK system.  Assays were run 
at 30°C on Greiner Bio One black 96-well microplates.  AR2G biosensors (Pall fortéBIO Corp.) 
were used to immobilize a chemokine of interest, CXCL12. Purified CXCL12 trap was prepared 
in an assay buffer (1× PBS, 0.002% Tween 20, pH 7.4) and applied to a 96-well microplate in 
column arrangement. Various concentrations of trap (0-500 nM) were used to test the binding. 
Assays were run in triplicate. All data were acquired and analyzed with fortéBIO Data Acquisition 
6.4 software.  Data processing was performed by averaging the reference biosensors, applying 
Savitzky-Golay filtering, and fitting binding curves using global fitting and a 1:1 model.  
2.3.6 CT-26(FL3) (RFP/Luc) culture 
CT-26(FL3) cells were obtained from Dr. Maria Pena’s lab at the University of South 
Carolina 44, and cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L glucose 
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(Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin 
(Gibco) at 37°C and 5% CO2 in a humidified atmosphere. Lentivirus transfection of the cell line 
was performed by incubating CT-26(FL3) cells in medium containing lentivirus.  Cells stably 
transfected with the vector carrying the mCherry red fluorescent protein (RFP), firefly luciferase 
(Luc), and the puromycin resistance gene were analyzed under fluorescent microscope. Stably 
transfected CT-26(FL3) cells were selected in the presence of puromycin. 
2.3.7 4T1 (GFP/Luc) culture 
4T1 (GFP/Luc) cells were cultivated in RPMI-1640 (Gibco) supplemented with 10% FBS 
(Gibco) and 1% penicillin/streptomycin (Gibco) at 37°C and 5% CO2 in a humidified atmosphere. 
To transfect the cell line, 4T1 cells were incubated in medium containing lentivirus.  Cells stably 
transfected with the vector carrying GFP, firefly luciferase (Luc), and the puromycin resistance 
gene were analyzed under a fluorescent microscope. Stably transfected 4T1 cells were selected in 
the presence of puromycin. 
2.3.8 HT-29 cell culture 
HT-29 cells were obtained from the tissue culture facility at the University of North 
Carolina Chapel Hill, and cultivated in McCoy’s 5a (Corning) supplemented with 10% FBS 
(Gibco) and 1% penicillin/streptomycin (Gibco) at 37°C and 5% CO2 in a humidified atmosphere.  
2.3.9 In vitro suppression of migration and invasion via CXCL12 trap protein 
The Chemotaxis 96-well Cell Migration and 24-well Cell Invasion Assays (EMD Millipore) 
were used to characterize the ability of the engineered protein (CXCL12 trap) to suppress CT-
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26(FL3) migration and invasion. Cells were seeded and starved for 24 hours on the transwell plates 
at a density of 0.5 X106 cells/ml in a serum-free medium. One group of cells remained in serum-
free medium, while all other groups were exposed to the chemokine (chemoattractant) CXCL12 
(10 nM) in the feeder (bottom) tray. Migration and invasion were measured in cells with CXCL12 
alone or in the presence of the engineered protein CXCL12 trap (60, 120, 240, or 360 nM) or 
positive control, a commercially available CXCL12 mAb (Abcam; 6, 12, or 24 nM). Assays were 
incubated at 37°C in a 5% CO2 environment for 4 and 24 hours for migration or 24 hours for 
invasion. Cells were dislodged from the underside of the membrane of the transwell, collected, 
and lysed. Lysis buffer was added along with luciferin (luciferase assay solution), which was 
analyzed through a bioluminescent plate reader. The background was subtracted and quantification 
was reported relative to untreated cells (no CXCL12 chemoattractant).      
2.3.10 Preparation of LCP loaded with pDNA  
LCP was prepared using a modified protocol 2. Two separate microemulsions (60 mL each) 
of Igepal 520 and cyclohexane (3:7 v/v) were prepared and placed under stirring. A pDNA (540 
μg) solution was prepared, then 1,800 μL of 2.5 M CaCl2 was added and allowed to stir for 5 min. 
To this solution, octaarginine peptide (mc-CR8C) was added at an N:P ratio of 2:1 (~600 µg), and 
this solution was immediately added to the microemulsion before precipitation could occur. A 
(NH4)2HPO4 solution (1,800 μL, 50 mM) was also prepared and added to the other microemulsion. 
Each microemulsion was stirred for 20 min. The microemulsion containing (NH4)2HPO4 was 
added to the microemulsion containing the DNA, peptide, and CaCl2. This solution was stirred for 
5 min before addition of 1,200 μL of 20 mM DOPA (in CHCl3). After addition of DOPA, the 
microemulsion was left to stir for an additional 30 min. An equal volume of 100% EtOH (120 ml) 
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was added to disrupt the emulsion. The mixture was centrifuged at 10,000g for 20 min. After 
decanting the supernatant, the precipitate was washed, vortexed, and sonicated twice with 100% 
EtOH to remove traces of Igepal and cyclohexane. The precipitate was then suspended in CHCl3. 
This solution was centrifuged at 12,000 rpm for 10 min to remove large aggregates, and the 
supernatant containing the LCP “cores” (DNA and peptide entrapped within a calcium phosphate 
nanoprecipitate, supporting and surrounded by a lipid monolayer of DOPA) was recovered. A 
single batch typically produced about 45 mg of cores, encapsulating about 250 µg pDNA. The 
ratio of cores to outer leaflet lipids for optimal final particle formulation was found to be 4.5 mg 
core:  225 µl DOTAP (20 mM): 225 µl cholesterol (20 mM): 200 µl DSPE-PEG2000 (20 mM). 
35 mol % DOTAP, 35 mol % cholesterol, and 30 mol % DSPE-PEG2000 (or 25 mol % DSPE-
PEG and 5 mol % DSPE-PEG-Gal) were used as outer leaflet lipids. 0.5% (w/w) Tween 80 was 
added to the chloroform solution containing the cores and outer leaflet lipids. The final particles 
were prepared for injection after formation of lipid film through drying off chloroform with 
nitrogen gas, then resuspension in 10% aqueous sucrose solution and sonication. Zeta potential 
and particle size of LCP were measured using a Malvern ZetaSizer Nano Series. Transmission 
electron microscopy (TEM) images of LCP were acquired using a JEOL 100CX II TEM. 
2.3.11 Characterization of LCP loaded with pDNA  
DNA entrapment was characterized by several methods. First, pDNA was labeled with Cy3 
(Mirus LabelIT kit, Mirus Bio) per manufacturer instructions. Cy3-DNA was formulated into the 
LCP cores, after which recovery was assessed by fluorescence spectrometry. Additional studies 
used Hoechst nucleic acid stain to confirm DNA entrapment efficiency or the extent to which 
pDNA and peptide were encapsulated in cores. Cores were collected, dried, and suspended in 
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acetic acid buffer (pH=4) to achieve core lysis. The peptide/DNA complex was dissociated by 
adding and incubating with protease K at 37°C for 1 hour. After incubation, Hoechst stain was 
added and samples were assessed via fluorescence spectrometry. Standard curves were generated 
using blank LCP cores along with known concentrations of peptide/pDNA complexes and used to 
calculate pDNA encapsulation efficiency (50-60%).  
2.3.12 Pharmacokinetics, biodistribution, and cellular distribution of gal-LCP-pDNA/mc-
CR8C  
Pharmacokinetics and quantitative biodistribution were determined by co-encapsulation of 
pDNA with 177Lu. 177Lu-labeled LCP cores were prepared as described above. The pDNA/peptide 
along with 177LuCl3 were mixed into the CaCl2 solution. This mixture was immediately added to 
the igepal/cyclohexane solvent to form the calcium emulsion. After co-precipitation of the calcium 
with the phosphate emulsions, 177Lu-labeled LCP cores were collected as described above. The 
final LCP cores encapsulated 80% of 177Lu. Final Gal-LCP-pDNA/mc-CR8C was produced by 
desiccation of a mixture of free lipids and cores and rehydration via 10% aqueous sucrose solution. 
Such methods have been utilized previously to accurately determine LCP biodistribution 2. 8-
week-old BALB/c female mice (6 mice for each group) were injected individually with LCP (0.2 
mL, balanced in osmolarity with the addition of sucrose) at 0.5 mg pDNA/kg, corresponding to a 
dose of 1 × 108 cpm/kg of 177Lu. For pharmacokinetic analysis, blood was recovered at various 
time points (0.5, 1, 2, 4, 8, 12, and 16 hours) via tail-nick bleed. For biodistribution analysis, 16 
hours after the administration of LCP, the blood and major organs were collected (6 mice for each 
time point). Radioactivity in the blood and tissues in both studies was measured using a γ-counter. 
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Analysis was conducted under a two-compartment model utilizing Phoenix WinNonlin (Version 
6.3, Pharsight Corporation). 
2.3.13 In vivo gene dose escalation and expression time profile  
A formulation of galactose-targeted LCPs containing pGFP or pCXCL12 Trap DNA, 
including a His(6x)-Tag at the C-terminal end, was injected (0.2 mL, balanced in osmolarity with 
the addition of sucrose) into 8-week-old BALB/c female mice (0.1, 0.5, or 1 mg DNA/kg, 3 mice 
for each group) through the tail vein. Mice were sacrificed 24 hours after administration. Liver, 
spleen, lungs, kidney, heart, and blood were collected and homogenized in RIPA buffer. Total 
protein concentration in the lysate was determined with a bicinchoninic acid protein assay kit 
(BCA Protein Assay Kit, Pierce). Subsequently, 50 µg of total protein was loaded for Western 
analysis. The desired CXCL12 trap protein has a molecular weight of 28.6 kD. GAPDH was used 
as a loading control, except for serum samples in which GAPDH is not present and therefore only 
BCA was used. His (6x)-tag mouse antibody was used as the primary antibody. The expression of 
pCXCL12 trap was quantified as the relative HRP intensity increase over the PBS-treated group. 
His-tag ELISA kit was also used, with 5 µg of total protein loaded for expression analysis. The kit 
provided standard proteins containing a His (6×)-tag to be used as a standard calibration control. 
After the dose escalation and expression studies, the 0.5 mg DNA/kg dose was chosen for further 
studies. Major LCP-accumulating organs were microscopically analyzed using rhodamine-
phalloidin and DAPI staining of frozen sections, as well as detection of cellular GFP expression, 
on days 2, 4, and 8 days after final tail vein administration of pGFP LCP (0.5 mg pDNA/kg x 3 
every other day). After the injections, mice were euthanized on days 2, 4, and 8. Organs were 
collected, rinsed in PBS, and fixed for 24 hours in 4% paraformaldehyde (PFA) solution. After 
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fixing, organs were placed in a 30% sucrose/PBS solution for 48 hours, then transferred to blocks 
containing OCT and placed in dry ice for freezing. The organs were sectioned, stained, and 
analyzed for GFP expression on a Nikon eclipse Ti fluorescent microscope with 10× objective. 
Fluorescent intensity was quantified using Image J software and reported as relative fluorescent 
intensity (average relative GFP expression). 
2.3.14 Toxicity and pathology studies  
Mice were treated with pCXCL12 trap, pGFP, or empty LCP (0.5 mg DNA/kg x 3, every 
other day; three mice for each group) and analyzed for toxicity 24 hours after final injection. 
Another treatment group was treated with purified CXCL12 trap protein (1.0 mg protein/kg x 3, 
every other day) and analyzed for toxicity markers on days 1, 7, and 14 after final injections. Serum 
was obtained from the mice via cardiac puncture and centrifugation. Hepatic and renal damage 
was assessed by measuring the concentrations of AST, ALT, creatinine, and BUN in the serum 
samples. Blood cell counts, including total white blood cells, lymphocytes, granulocytes, and 
monocytes were measured with whole blood analysis. These measurements were quantified by the 
Animal Clinical Chemistry and Gene Expression Laboratories at UNC Chapel Hill. Further, the 
major organs of each mouse were collected, fixed in 4% PFA, and processed with trichrome 
staining. Tissue sections were imaged using a Nikon light microscope with 10× objective. 
2.3.15 Orthotopic allografting in mice 
Sub-confluent cells were harvested and washed in PBS just before cecal or spleen 
implantation. Eight-week-old male BALB/c or nude mice were anesthetized by IP injection of 
ketamine/xylazine solution (140 µL, 10 mg-2 mg/ml) and placed in supine position. For cecum 
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inoculation, a midline incision was made to exteriorize the cecum. Using an insulin-gauge syringe, 
2×106 CT-26(FL3) cells in 25 µL were injected into the cecum subserosa. Light pressure was 
applied to the injection site to prevent any leakage of injected material, followed by sterilization 
with 70% alcohol to kill cancer cells that may have leaked out. The cecum was returned to the 
peritoneal cavity. 
  The establishment of an aggressive liver metastasis model in which the primary tumor is 
resected followed the protocol developed by Kasuya et al.45. For splenic inoculation, an incision 
was made below the left rib cage to exteriorize the spleen. The spleen was tied and cut into two 
parts, each containing the intact vascular pedicle for half of the spleen. The distal section of the 
spleen was inoculated with 1x106 HT-29 or 4T1 (GFP/Luc) cells in 100 µL. The hemi-spleen 
containing inoculated cells remained for 10 minutes to allow escape of the cancer cells into the 
portal vein. The hemi-spleen containing inoculated cells was then resected to model primary tumor 
resection. The other half of the spleen was returned to the cavity, and the abdominal wall and skin 
were closed with 4-0 polyglycolic acid sutures.  
2.3.16 Luciferase imaging of whole animals and ex vivo tissues 
Luciferase imaging of tissue and animals was performed as follows:  D-luciferin, 1.0 mg/ 
10 g body weight, was injected intraperitoneally into mice. 10 min after administration, luciferase 
imaging (IVIS-Kinetic) was performed on whole mouse bodies. For ex vivo imaging, mice were 
dissected 10 min after luciferin injection. Intestine and other organs were quickly rinsed in PBS 
and placed in diluted luciferin solution (2 mg/ml) for 1 min. Organs were then placed in culture 
dishes and luciferase imaging was applied immediately. Imaging and quantification were 
performed at the UNC Biomedical Research Imaging Center (BRIC) using the IVIS kinetic optical 
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imaging system. Quantification of bioluminescent signal was either reported as the raw average 
intensity or log-normalized.  
2.3.17 Immunohistochemistry 
Histology and immunohistochemistry were performed on paraffin-embedded or frozen 
sections from major organs and organs containing metastatic lesions. All paraffin-embedded tissue 
was resected, rinsed in PBS, and placed in 4% PFA for 48 hours at 4°C. After 4% PFA, tissues 
were rinsed in water and placed in 70% ethanol solution until paraffin-embedded. All tissues for 
frozen sections were resected and rinsed in PBS, and placed in 2% PFA overnight at 4°C. After 2% 
PFA, tissues were placed in 30% sucrose/PBS solution overnight at 4°C. Tissues were snap frozen 
in O.C.T. (Fisher Scientific). Immunofluorescence staining was performed by deparaffinization, 
antigen retrieval, permeabilization, and blocking in 1% bovine serum albumin at room temperature 
for 1 hour. Primary antibodies conjugated with fluorophores (BD) were incubated overnight at 
4°C, and the nuclei were counterstained with 4',6-diamidino-2-phenylindole-containing mounting 
medium (Vector Laboratories). All antibodies were diluted after optimization. Images were taken 
using fluorescence microscopy (Nikon). A minimum of three randomly selected microscopic fields 
were quantitatively analyzed using Image J software. 
2.3.18 In vivo liver metastasis CT-26(FL3) (RFP/Luc) study   
Mice were inoculated with 2x106 CT-26(FL3) RFP/Luc cells into the cecum wall. 
Treatment consisting of 10 µg (pDNA) Gal-LCP-pCXCL12 trap/mc-CR8C was administered on 
days 10, 12, and 14 through tail vein IV (n=7). Control groups included PBS/untreated (n=7) and 
Gal-LCP-GFP/mc-CR8C (n=6).  Progression of tumor mass was followed by administration of 
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200 µl luciferin (10 mg/ml) IP. Luciferase bioluminescent imaging was performed 10 min after 
administration of luciferin. On day 24, mice were imaged, sacrificed, and organs were extracted 
and placed in a solution of luciferin (1 mg/ml) and imaged for bioluminescence. Quantification of 
tumor burden in livers was performed using Image J software.  
2.3.19 In vivo liver metastasis 4T1 (GFP/Luc) study   
Mice were inoculated with 1x106 (100 µL) 4T1 (GFP/Luc) cells into one half of the spleen. 
Groups included 10 µg (pDNA) Gal-LCP-pCXCL12 trap/mc-CR8C on days 0-6 (every other day) 
administered through tail vein IV along with IP administration of isotype IgG or anti-Lyt2.2 (400 
µg) on days 0 and 2 (n=8), PBS/untreated (n=8), and Gal-LCP-GFP/mc-CR8C along with IP 
administration of anti-Lyt2.2 (400 µg) on days 0 and 2 (n=8). Progression of tumor mass was 
followed by administration of 200 µl luciferin (10 mg/ml) IP. Luciferase bioluminescent imaging 
was performed 10 min after administration of luciferin. On day 7, mice were imaged (n=5 per 
group). On day 10, 3 mice from each group were euthanized. Livers were collected and strained 
through 70 µm cell strainer. Cells were fixed in a 2% PFA/PBS solution for 15 min followed by 
flow cytometry analysis to determine percentage of tumor (GFP+) population. Primary 4T1 
(GFP/Luc) tumor was used as the GFP-positive control.  Mice were euthanized when any of the 
following symptoms were observed: body weight change of 10% from day 0, inactivity, 
dehydration, or weakness/shortness of breath. Survival was recorded, and organs were collected, 
weighed, and analyzed for number of metastatic lesions. 
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2.3.20 In vivo liver metastasis HT-29 study   
Mice were inoculated with 1x106 (100 µL) HT-29 cells into one half of the spleen. Treatment 
consisting of 10.0 µg (pDNA) Gal-LCP-pCXCL12 trap/mc-CR8C on days 0-16 (every other day) 
was administered through tail vein IV (n=5). Control groups included PBS/untreated (n=5), Gal-
LCP-GFP/mc-CR8C (n=5), AMD3100 (100 µg, n=5), and free CXCL12 trap protein (10 µg, n=5).  
Mice were euthanized on day 36 after inoculation. Organs were collected and analyzed for the 
presence of metastatic lesions. Metastatic nodules were resected from the livers and weighed.  
2.4 Results 
2.4.1 Engineered CXCL12 trap reduces migration/invasion of CXCL12-stimulated CT-  
26(FL3) cells 
The CXCL12 trap gene was designed based on known anti-CXCL12 antibody sequences. 
This was accomplished by fusing a VH and a VL domain through a protease-resistant flexible linker. 
Subsequently, a strong signaling peptide from human serum albumin preproprotein was 
incorporated at the N-terminus to efficiently facilitate the secretion from liver hepatocytes after 
expression 46, whereas E and His(6×)  tags were introduced at the C-terminus to facilitate protein 
purification and in vivo expression analysis. The coding sequence of the CXCL12 trap was cloned 
into the expression vector pCDNA3.1, driven by a cytomegalovirus (CMV) promoter. The 
recombinant CXCL12 trap was expressed in and purified from 293 T cells. The target-binding 
features, such as the binding affinity and specificity for CXCL12 and other chemokines, were 
measured through Bio-Layer Interferometry (BLI) (Figure 2-3A). The engineered CXCL12 trap 
was found to have a dissociation constant of 4.0 nM for CXCL12 (Figure 2-3A). It has been 
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reported that treatment of CT-26(FL3) cells with the recombinant CXCL12 chemokine yields 
upregulation of the migration/invasion pathways 39 40. Therefore, the ability of the CXCL12 trap 
(Trap) and a commercially available CXCL12 antibody (Ab) to suppress the migration and 
invasion of CT-26(FL3) cells down a concentration gradient of CXCL12 was investigated (Figure 
2-3B/C). Although the in vitro half-maximal inhibition [ND50] is not a direct indicator of affinity 
of the CXCL12 trap or antibody to the CXCL12, these in vitro experiments demonstrated the 
Trap’s ability to decrease the migration and invasion of CT-26(FL3) (RFP/Luc) cells down a 
concentration gradient of CXCL12 (10 nM). The results indicate complete suppression of the 
migration and invasion at a Trap concentration of 240 nM (Figure 2-3B/C). The CXCL12 trap 
produced ND50 against biologically active CXCL12 (10 nM) in vitro at a concentration of 
approximately 120 nM (Figure 2-3B/C). Commercially available CXCL12 antibody (ND50 of 12-
24 nM) was used as a positive control (Figure 2-3B/C). 
2.4.2 Formulation and characterization of galactose-LCP pDNA/mc-CR8C nanoparticles  
Hu et al. reported the formulation and delivery of the galactose-LCP with pDNA/mc-CR8C 
cargo to the liver hepatocytes of mice 2. The core structure can be visualized under transmission 
electron microscopy (TEM) (Figure 2-4A). The 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) 
monolayer surrounding the CaP core allows for the addition of the cationic outer leaflet lipids, 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP), helper lipid cholesterol, and galactose 
conjugated to 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-succinyl(polyethylene 
glycol)-2000 (GAL-DSPE-PEG2000) to assist in RES evasion and hepatocyte uptake, producing 
the final LCP particles (40–60 nm in diameter, shown in Figure 2-4B/C). The hydrodynamic 
diameter and the surface charge of the LCP particles were found via dynamic light scattering 
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zetasizer analysis to be approximately 45 nm and 10 mV, respectively (Figure 2-4C). The excess 
lipids not incorporated into the outer lipid layer of the LCP form liposomes with an approximate 
diameter of 350 nm. The LCP and liposome mixture result in a z-average of 236±32 nm; n=6. The 
solution was found to be stable in 10% fetal bovine serum for at least 24 hours at 37°C in which 
no significant increase in the z-average was observed (Figure 2-4D). The pDNA encapsulation 
efficiency was found to be approximately 50-60%, which corresponds closely to the reported 
formulation by Hu et al. 2. Liver-specificity, pharmacokinetics (PK), and organ distribution were 
determined through incorporation of 177Lu radioisotope along with the nuclear localizing signal 
(NLS) peptide/pDNA into the LCP core. The LCP particles containing 177Lu were injected through 
the tail vein into healthy BALB/c mice. The PK and organ distribution profile studies demonstrate 
that the galactose-LCP nanoparticles exhibit a two-phase distribution with a T1/2α and T1/2β of 20 
and 1,054 min, respectively, as well as approximately 50% of the injected dose per gram tissue 
accumulating in the liver 16 hours after IV injection (Figure 2-5).  
2.4.3 In vivo expression profile of pDNA (pGFP and pTrap) via LCP formulation 
Hu et al. reported that the majority of pDNA encapsulated in the highly PEGylated LCP 
vector was delivered and expressed in the hepatocytes. Furthermore, the decreased PEG density 
and the absence of galactose-targeting ligand shifted the uptake preferentially into the Kupffer 
cells, decreasing expression of the pDNA2. Therefore, to ensure hepatocyte uptake and expression, 
a high PEG density (30% mol. input) and galactose targeting ligand (5% mol. input) throughout 
the formulation of the pDNA LCP vector was used. The preferential expression of the Green 
Fluorescent Protein Plasmid (pGFP) and CXCL12 trap plasmid (pTrap) in the liver versus other 
organs/serum to ensure preferential liver-specific expression of the delivered pDNA was 
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investigated. pGFP LCP was administered via IV injection to observe GFP expression in the liver 
(Figure 2-6A). Transient liver-specific expression lasting up to 4 days was observed through 
fluorescent microscopy analysis of organ sections on day 2, 4, and 8 after final pGFP LCP injection. 
No GFP signal was found in any other major organ sections. Furthermore, expression of GFP was 
found to be predominately in the hepatocyte population within the liver (Figure 2-7). Subsequently, 
expression of the CXCL12 trap was assessed by ELISA and Western blot analysis using the 
His(6×)-tag engineered at the C-terminus of the CXCL12 trap (Figure 2-6B/C). Mice were treated 
with increasing doses of pTrap LCP (0.1 mg/kg, 0.5 mg/kg, and 1.0 mg/kg). A dose-dependent 
increase in liver expression 24 hours after intravenous injection, with no significant expression 
found in other major organs or serum was observed through ELISA and Western blot analysis, 
(Figure 2-6B). Further Western blot studies demonstrated the transient expression time profile in 
which pTrap LCP (10 µg pDNA, 0.5 mg/kg every other day x 3) was administered intravenously 
followed by collection of the livers on days 1, 2, 4, and 8 after final LCP administration (Figure 2-
6C). The results indicate that the pDNA LCP vector elicits transient liver-specific expression of 
the CXCL12 trap, similar to the GFP expression profile, yielding expression for at least 4 days 
after final injection (10 µg pDNA; 0.5 mg/kg every other day x3) (Figure 2-6A/C). These results 
demonstrate that the galactose-LCP vector allows for preferential transient expression in the 
hepatocytes, with minimal expression in other organs or serum (Figure 2-6). 
2.4.4 Modifying CXCL12 expression and immune cell populations in the liver of CRC mice  
  Colorectal liver metastasis was established through injection of 2 x 106 CT-26(FL3) cells 
into the mouse cecum wall. Zhang et al. reported that initial micro-metastatic lesions form 14 days 
after inoculation of cells. The formation of large metastatic lesions and euthanasia of the mice 
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because of large primary tumors in the intestine was reported 4 weeks after inoculation 44, which 
corresponded closely to the observed results. Therefore, prophylactic liver metastasis treatment 
with pTrap LCP (10 µg, 0.5 mg/kg pDNA every other day x 3) was initiated 10 days after 
inoculation, before the formation of measurable liver metastases. The efficacy of the pTrap LCP 
to decrease CXCL12 concentrations as well as inflammation and the number of metastatic lesions 
within the liver was assessed following IV administration (Figure 2-8A). The expression of 
endogenous CXCL12 in the liver of CRC-bearing BALB/c mice was investigated in liver sections 
through immunofluorescent staining for CXCL12. The amount of CXCL12 found in the livers of 
CRC mice was compared to sections obtained from normal (healthy) mice without CRC to better 
understand the shifts in the endogenous expression of CXCL12 in the CRC liver metastasis model. 
The livers were assessed on day 24 (10 days after final injection) by staining for CXCL12 (red, 
Figure 2-8A). Five groups were investigated, four of which contained CRC, as follows: healthy 
(No CRC), untreated (treated with phosphate-buffered saline, PBS), pGFP LCP control (10 µg 
every other day x 3), pTrap LCP (10 µg single injection), pTrap LCP (10 µg every other day x 3). 
Figure 2-8A shows that the untreated and pGFP-treated CRC mice had comparable expression of 
CXCL12 and that it was 5- to 6-fold higher than in the healthy livers from mice without CRC. The 
increased CXCL12 is believed to be a result of inflammation induced by the presence of the 
metastatic lesions. However, pTrap LCP (10 µg and 10 µg every other day x 3) treatment resulted 
in 2.5 and 5-fold decreases in fluorescent intensity, respectively, compared to the untreated animals, 
reaching baseline expression of CXCL12 in the group that received 3 doses of the Trap (Figure 2-
8A). Endogenous expression of CXCL12 in major organs of healthy mice (No CRC) is shown in 
Figure 2-9.  Having observed the reduction in liver CXCL12 after treatment with pTrap LCP, 
further immunofluorescence staining of the tissue sections was used to determine the effect of 
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treatment on the liver immune cell populations, including MDSCs, regulatory T cells (T-reg), and 
CD8+ T cells (Figure 2-8B). These immune cells have substantial CXCR4 expression and 
therefore are recruited by endogenous CXCL12 47. Four groups were studied, including sections 
from the livers of healthy mice (No CRC), untreated livers containing metastatic lesions (Tumor), 
untreated livers containing increased collagen (Stroma), as well as those treated with pTrap LCP 
(10 µg every other day x 3), in which metastatic lesions were not observed. The staining indicated 
that there is a drastic increase in the MDSCs, T-reg, and CD8+ T cell population in the untreated 
(Tumor and Stroma) groups compared to the healthy (No CRC) group. The pTrap LCP treated 
group had low numbers of MDSCs and T-reg, similar to the healthy livers (No CRC). However, 
an increase was observed in the CD8+ T cell population in the pTrap LCP group compared to the 
healthy (No CRC) group. It must be noted, however, that this amount of CD8+ T cells was still 
two-fold lower than in the untreated groups, in which metastatic lesions and inflammation were 
present (Figure 2-8B). This is consistent with the metastatic lesions’ ability to cause local 
inflammation, which results in increased CXCL12 and a subsequent influx of anti- and pro-
inflammatory immune cells into the liver (Figure 2-8B). Although the untreated CRC livers had 
the highest influx of CD8+ T cells, the large numbers of immunosuppressive MDSCs and T-reg 
populations are likely to neutralize the CD8+ T cells before they can mediate cancer-specific 
killing. However, after pTrap treatment, the moderate increase in the CD8+ T cell population in 
the presence of minimal immunosuppressive cells may allow for adequate surveillance and cancer-
specific killing before the immunosuppressive metastatic lesion is formed. 
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2.4.5 Therapeutic efficacy of pTrap LCP in an orthotopic syngeneic colorectal liver metastasis 
mouse model 
The effect of pTrap LCP on the incidence of liver metastasis in mice was investigated. 
Mice were inoculated with 2.0x106 CT-26(FL3) (RFP/Luc) cells orthotopically into the cecum 
wall. Three treatment groups were evaluated, including untreated (PBS), a vector/pDNA control 
(pGFP LCP), and pTrap LCP. Administration of treatment began on day 10 after inoculation, when 
IV tail vein injections (10 µg, 0.5 mg/kg pDNA) were administered on day 10, 12, and 14.  The 
total tumor burden was monitored by intraperitoneal (IP) administration of 200 µL of luciferin (10 
mg/ml) followed by bioluminescent analysis 10 min after luciferin administration. The tumor 
burden was recorded weekly and used to sort mice into treatment groups before day 10. The tumor 
burden on day 24 is shown in Figure 2-10. On day 24, mice were imaged and euthanized due to 
heavy primary tumor burden in the cecum. Livers and other organs were harvested and analyzed 
by bioluminescent imaging to determine metastatic tumor burden (Figure 2-11A/B). After 
bioluminescent analysis, livers were fixed, sectioned, and trichrome stained for further 
morphological analysis (Figure 2-11C). Mice treated with PBS or pGFP LCP developed large 
metastatic tumor lesions in the liver (Figure 2-11A/B), which caused prominent fibrotic tissue and 
cirrhosis (Figure 2-11C).  In contrast, mice treated with pTrap LCP (10 µg pDNA) three times 
showed a 10-fold reduction in liver metastasis burden and approximately a 70-80% decrease in the 
incidence of liver metastasis formation (Figure 2-11A/B). The fibrotic area detected by 
microscopic analysis of the trichrome stained liver sections was significantly smaller in specimens 
from pTrap LCP mice than control specimens (p=0.0001) (Figure 2-11C).  Although the rate of 
liver metastasis was reduced, the primary and distal tumor burden outside of the liver remained 
unchanged with this treatment (Figure 2-11B).    
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2.4.6 Cancer-specific T cells enhance the anti-metastasis efficacy of pTrap LCP therapy 
The decreased MDSCs and T-reg populations in the liver after pTrap LCP treatment, along 
with the presence of CD8+ lymphocytes, implicate a shift from a pro-tumor (immunosuppressive) 
to anti-tumor environment within the liver. Therefore, the cytotoxic T lymphocytes’ (CTLs’) 
ability to decrease the establishment of metastasis in the liver after pTrap LCP therapy was 
examined. To investigate the pTrap LCPs’ ability to enhance cancer-specific CD8 T-cell killing, 
the anti-cancer efficacy of the pTrap LCP in mice with a depleted CD8+ T-cell population was 
examined. A protocol similar to that reported by Harimoto et al. was followed, in which ≥95% of 
the CD8+ T cell population was depleted after two intraperitoneal injections of 400 µg anti-Lyt2.2 
(2.43; rat IgG2b)48. Mice were inoculated with CRC per the orthotopic syngeneic model described 
earlier, followed by T cell depletion before treatment. In this series of experiments, treatments 
began 10 days after cecum inoculation. The animals were divided into three treatment groups: 
untreated (PBS), pTrap LCP with anti-CD8 (Anti-Lyt2.2), and pTrap LCP with an antibody 
isotype control (rat IgG2b isotype control). To maintain the depletion of the CD8+ T cell 
population, an intraperitoneal injection of the Anti-Lyt2.2 or isotype control IgG (400 µg) was 
administered on day 8 and 10.  Treatment was initiated on day 10 after inoculation, with IV tail 
vein injection (10 µg pDNA) on days 10, 12, and 14. Mice were euthanized because of heavy 
primary tumor burden in the cecum on day 21, and the liver tumor burden was determined through 
bioluminescent imaging (Figure 2-12). All mice treated with the PBS developed large metastatic 
tumor lesions in the liver (Figure 2-12). The T cell-depleted mice treated with anti-Lyt2.2 followed 
by three doses of pTrap LCP (10 µg pDNA) showed similar liver tumor burden to the untreated 
mice. In contrast, mice treated with the isotype control IgG2b antibody followed by pTrap LCP 
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showed a 5-fold reduction in liver metastasis burden and approximately 80% decrease in the 
incidence of liver metastasis compared to untreated animals. These results show that the presence 
of CTLs along with reduction in CXCL12 decreases the risk of establishing metastatic lesions in 
the liver.  
2.4.7 Reduced metastatic burden is associated with increased survival in breast cancer liver 
metastasis model  
The effect of pTrap LCP on the median survival and liver tumor burden in an aggressive 
mouse breast cancer liver metastasis model was investigated. The breast cancer liver metastasis 
model consists of the hemi-splenic implantation of a highly metastatic murine breast cancer cell 
line 4T1. These studies modeled the clinical standard of care, in which the primary tumor is 
resected and death usually results from the metastatic burden. BALB/c mice were inoculated with 
1.0x106 (0.1 mL) of 4T1(GFP/Luc) cells into one half of the spleen, which had been tied off and 
separated into two halves before the tumor inoculation. The hemi-spleen that received the cells 
was resected 10 min after inoculation to decrease primary tumor growth. In this series of 
experiments, treatments began on the day of inoculation because of the rapid migration of cells to 
the liver, often within 5 min after inoculation 49. The four treatment groups for the breast cancer 
liver metastasis model included: untreated (PBS), pGFP LCP with anti-CD8 (10 µg, 0.5 mg/kg 
pDNA and 400 µg, 20 mg/kg anti-Lyt2.2), pTrap LCP with anti-CD8 (10 µg, 0.5 mg/kg pDNA 
and 400 µg, 20 mg/kg anti-Lyt2.2), and pTrap LCP with isotype IgG (10 µg, 0.5 mg/kg pDNA 
and 400 µg, 20 mg/kg Isotype IgG). PBS, pGFP LCP, or pTrap LCP was administered IV via tail 
vein injections every other day starting on day 0 and ending on day 6. Administration of the anti-
Lyt2.2 or Isotype IgG control involved two IP injections on days 0 and 2. Tumor progression was 
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monitored by bioluminescent imaging (Figure 2-13A). Mice were euthanized when one of the 
following conditions applied: drastic weight gain or loss greater than 10% within one week or clear 
signs of distress, such as dehydration, inactivity, or shortness of breath/weak breathing.  Three 
mice from each group were euthanized 10 days after inoculation, their organs were collected and 
rinsed in PBS, and the livers were analyzed for tumor burden by flow cytometry analysis (Figure 
2-13B). Mice that did not receive pTrap LCP treatment developed large metastatic tumor lesions 
in the liver within the first week after inoculation (Figure 2-13A/B).  In contrast, mice treated with 
pTrap LCP showed a reduction in liver metastasis burden and decrease in the incidence of liver 
metastasis formation, as well as an almost 2-fold increase in the median survival versus all other 
treatment groups (14 vs 25 days) (Figure 2-13C). 
2.4.8 Reducing the establishment of liver metastasis by pTrap LCP, Trap protein, and CXCR4 
antagonist  
The efficacy of different therapeutic modalities [anti-CXCL12 trap protein, CXCR4 small 
molecule antagonist (AMD3100), and the pTrap LCP] in reducing the establishment of liver 
metastasis using a human colorectal cancer cell line (HT-29) in immunodeficient athymic mice 
was investigated. The human colorectal cancer liver metastasis model was established per the same 
hemi-splenic implantation procedure as above, using colorectal cancer cell line HT-29, which has 
high expression of CXCR4 (Figure 2-1). In this series of experiments, treatments again began on 
the day of inoculation because of the rapid migration of cells to the liver within 5 min after 
inoculation 49. The five treatment groups studied for the colorectal cancer liver metastasis model 
were untreated (PBS), pGFP LCP (10 µg, 0.5 mg/kg pDNA), pTrap LCP (10 µg, 0.5 mg/kg pDNA), 
free CXCL12 trap protein (10 µg, 0.5 mg/kg protein), and AMD3100 (100 µg, 5.0 mg/kg). The 
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treatments were administered IV by tail vein injection every other day, initiated on day 0 and 
terminated on day 16 (Figure 2-14A). Mice were euthanized on day 36, their livers were collected 
and rinsed in PBS, and tumor nodules were resected from the livers and weighed (Figure 2-14B). 
Mice that did not receive pTrap LCP or AMD3100 treatment developed numerous metastatic 
tumor lesions in the liver (Figure 2-14B).  In contrast, mice treated with pTrap LCP or AMD3100 
showed a reduction in liver metastasis burden and decreased incidence of liver metastasis 
formation during the treatment compared to all other treatment groups.  
2.4.9 Toxicity analysis of pTrap LCP and free CXCL12 trap protein  
Administration of pTrap LCP (10 µg every other day x 3) did not cause any significant 
changes in ALT, AST, creatinine, or BUN, and there were no signs of toxicity in trichrome-stained 
histology sections of any organ 24 hours after the final IV tail vein injection (Figure 2-15A/B). 
Analysis of blood cell counts showed no signs of change compared to untreated mice (Figure 2-
15A). However, analysis of mouse serum and whole blood samples after systemic IV injection of 
20 µg engineered CXCL12 trap protein (every other day x 3) identified transient elevations of ALT 
and AST on day 7 after final injection. In addition, the white blood cell counts drastically decreased 
between day 1 and 7, with a slight recovery of white blood cell counts by day 14 after final injection 
(Figure 2-15A).  Histological analysis of trichrome stained organ sections found no signs of 
toxicity for any of the treatment groups.  
2.5 Discussion and Conclusion 
To prime the liver to resist cancer invasion, critical factor(s) that play a pivotal role in cancer 
progression must be blocked. The decision to target CXCL12 stemmed from numerous studies 
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demonstrating the fundamental role that CXCL12 plays in upregulating cancer pathways and 
recruiting immunosuppressive cell types to the tumor microenvironment. CXCR4 is the most 
widely expressed chemokine receptor, with high expression in many different hematological and 
solid cancers 50. High expression of CXCR4 is associated with high rates of liver metastasis and 
poor survival 39. CXCR4 is activated by the exclusive binding of its ligand CXCL12. CXCL12 
activates essential signaling pathways, including epidermal growth factor receptor (EGFR), 
mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase/protein kinase B 
(PI3K/AKT), WNT, and NF-κB, which mediate cancer cell proliferation, growth, migration, 
invasion, and survival 51. Recent studies suggest that the stimulation of tumor cell proliferation via 
CXCL12 is MAPK-dependent 52 53. This CXCL12 stimulation can further be categorized as an 
autocrine mechanism, in which CXCL12 activates RAS and MAPK, allowing the production of 
various transcription factors including c-MYC. These transcription factors further upregulate the 
expression of CXCR4, resulting in enhanced sensitivity to CXCL12 51 54. Another study found 
inhibition of CXCL12/CXCR4 signaling decreased pancreatic cancer proliferation and 
progression in vitro via inactivation of the canonical WNT pathway 55.  Additionally, CXCL12 
influences tumor growth through activation of the PI3K/Akt pathway 52 53. The ability of CXCL12 
to drive tumor cell survival was also established in a study suggesting that CXCL12 expression 
activates NF-κB and suppresses apoptotic signaling 56.  
The progression of cancer from the primary lesion to distant metastatic lesions is the product 
of a highly organized and tissue-selective process. One such mechanism involves CXCL12 
directing metastasis to select tissues through the establishment of a chemokine gradient. The 
CXCL12 chemokine interacts with glycosaminoglycan on the surface of endothelial cells and in 
the extracellular matrix to produce a concentration gradient. This chemokine gradient directs 
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leukocyte and tumor cell migration towards a select tissue. Additionally, CXCR4 is expressed in 
CRC progenitor cells and plays a role in maintaining these cancer stem-like cells 40 41. Human 
breast cancer is another such example, where CXCR4 is highly expressed and stimulated by 
CXCL12 in both primary and metastatic lesions. CXCL12 is highly expressed in organs to which 
breast cancer disseminates, such as lung, bone, and liver. In vivo studies have demonstrated that 
neutralization of the CXCL12/CXCR4 axis impairs metastasis resulting from chemotactic and 
invasive responses in breast cancer models 57. CXCR4 is also involved in the metastasis of prostate 
cancer cells to the bone marrow, where a higher population of CXCR4 positive cells are found at 
the metastatic sites compared to the primary tumor 25 58.  
The research presented in this report demonstrates the therapeutic benefits of inhibiting 
CXCL12 in the liver of aggressive liver metastasis cancer models. Directly disrupting the 
activation of CXCR4 positive cancer cells by inhibiting CXCL12 in an immunodeficient colorectal 
cancer liver metastasis mouse model reduced the establishment of liver metastasis. Furthermore, 
in immunocompetent colorectal and breast cancer liver metastasis mouse models, it was 
demonstrated that disrupting the CXCL12/CXCR4 pathway also plays a crucial role in inhibiting 
the tumor immune microenvironment.  CXCL12/CXCR4 plays a critical role in the recruitment of 
leukocytes, plasmacytoid dendritic cells, MDSCs, and neutrophils to sites of inflammation 47. 
Studies have suggested that increasing amounts of CXCL12 are produced by the hepatic stellate 
cells during liver inflammation. This local increase in CXCL12 production drives recruitment and 
activation of tumor and immune cells to the microenvironment. These infiltrating cells provide an 
additional source of CXCL12 at the inflammation site (metastatic lesion), which further activates 
tumor growth, survival, angiogenesis, and metastasis. The results suggest that delivery of a 
CXCL12 trap to the liver not only disrupts cancer activation by inhibiting CXCL12/CXCR4 
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interaction, but further inhibits the recruitment of CXCR4+ immunosuppressive cells such as 
MDSCs and T-reg. Therefore, it is hypothesize that the therapy described in this dissertation works 
by two major pathways, directly inhibiting the CXCL12/CXCR4 stimulation of cancer cells, as 
well as reducing the recruitment of CXCR4+ immune suppressor cells to allow for increased 
cancer-specific CD8+ T cell killing. The local (liver) and transient (4 days) expression of the 
engineered CXCL12 trap has the potential to influence the immune response as well as the cancer 
biology driving the establishment of metastasis. These findings may provide a basis for future 
strategies for targeting metastatic lesions, in which the co-delivery of genes expressing traps 
against a chemokine such as CXCL12 and an immune checkpoint protein could work in a 
synergistic manner.  
Clinically, it has been suggested that the number of CXCR4+ colorectal cancer cells in a 
patient can be used as a biomarker to determine which patients may have a more aggressive and 
higher rate of liver metastasis 39 42. Therefore, patients with a high population of CXCR4+ cells 
may be optimal candidates for a treatment targeting the CXCL12/CXCR4 axis in conjunction with 
other therapies. However, it is also clear that endogenous CXCL12 plays a crucial role in leukocyte 
recruitment and therefore systemic administration of free anti-CXCL12 proteins would elicit 
serious toxicities. It was demonstrated that these toxicities can be avoided through the local and 
transient delivery of LCP gene vector. This pTrap LCP vector greatly decreased the occurrence of 
colorectal liver metastasis (80%) and drastically decrease the tumor burden found within the liver 
(10-fold). Increased concentrations of the CXCL12 trap as well as decreased concentrations of free 
CXCL12 protein were found in the liver in a dose-dependent manner. This approach also reduced 
the recruitment of immune suppressor cells (MDSCs and T-reg), demonstrating a biologically 
specific effect of pTrap LCP treatment. The insufficient target specificity of most small molecule 
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and protein therapies as well as the toxicity concerns that revolve around the use of viral vectors 
for gene therapy have limited the clinical applications. Furthermore, many non-viral vectors for 
gene therapy have fallen short because of extracellular and intracellular barriers in vivo. However, 
the delivery of pDNA in a LCP vector shows no signs of off-target effects, with minimal to no 
adverse immune response after repeated injections. The ability to have transient expression of this 
small CXCL12 trap (~28.6 kD) lasting up to about 4 days would allow clinicians to tightly control 
and monitor the extent and time of expression to limit undesired immune responses and still 
achieve therapeutic efficacy. Moreover, the in vivo pDNA dose used in the study (0.5 mg/kg per 
injection) is substantially lower than doses previously shown to have in vivo expression 1. In the 
past, therapeutic pDNA has only been successfully delivered to the liver via viral vectors or 
through invasive hydrodynamic injection 59. Therefore, a non-viral vector capable of delivering a 
therapeutic gene such as the CXCL12 trap should have high translatability to the clinic. 
Although this LCP platform as well as many other non-viral vectors have aimed to improve 
pDNA expression levels in vivo, expression levels of non-viral vectors still fall short compared to 
viral gene delivery systems. This gap can only be lessened through innovative technologies aimed 
at improving the limitations in nuclear localization and release of pDNA. Furthermore, the pre-
clinical animal models used to test a vectors therapeutic potential need to more accurately mirror 
the clinical profile. The use of cell line-based models and non-orthotopic implantation introduce 
artifacts which limit the capacity to measure the non-viral vectors ability to treat the clinical disease. 
These limitations need to be addressed to bring about successful translation of these gene delivery 
vectors to the clinic. 
 
 
 44 
 
 
Figure 2-1 Western blot analysis to evaluate endogenous CXCR4 expression in mouse and human 
cancer cell lines  
 
Cells were cultured in the conditions recommended by ATCC, lysed, and normalized by BCA for accurate 
protein loading. Each lane received 30 µg of total protein. All samples were run on same gel to ensure 
accurate exposure and relative expression. Protein was identified at 42 kDa using a protein standard ladder. 
Data were expressed as mean ± s.d., calculated from samples ran in triplicate and reported as intensity 
relative to the highest intensity sample [CT-26(FL3) and HT-29] and normalized by GAPDH intensity. N.S. 
denotes no significance, N.D. denotes under detection limit, p-values represent significance of the 
difference relative to the first cell line in graph. 
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GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCC
CATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAAC
GACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTT
CCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGT
ATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTAT
GCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG
GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAAC
GGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTA
CGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCT
TATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCCACCATGAAATGGG
TCACCTTTATCAGCCTGCTGTTCCTGTTCAGCAGCGCCTACAGCGGATCCGAGGTGCAGCTG
GTGGAATCTGGCGGAGGACTGGTGCAGCCTGGCGGCTCTCTGAGACTGTCTTGTGCCGCCAG
CGGCTTCAGCCTGACCGTGTACTCTGTGCACTGGGTGCGCCAGGCCCCAGGCAAAGGACTGG
AATGGGTGGGAGCCCTGTGGGGCTCTGGCGGAACCGAGTACAACAGCAACCTGAAGTCCCG
GTTCACCATCAGCCGGGACACCAGCAAGAACACCGTGTACCTGCAGATGAACAGCCTGCGG
GCCGAGGACACCGCCGTGTACTATTGCGCCAGAGATCAGGGCCTGAACTACGGCAGCCTGTT
CGACTATTGGGGCCAGGGCACACTCGTGACCGTGTCTAGCGGAGGCGGAGGAAGTGGCGGA
GGGGGATCTGGCGGCGGAGGCAGCGATATTCAGATGACCCAGTCCCCCAGCAGCCTGAGCG
CCTCTGTGGGCGACAGAGTGACCATCACCTGTCGGGCCAGCGAGAGCATCAGCTACAGCCT
GTCCTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAACGCCGTGAAG
CTGGAAAGCGGCGTGCCCAGCAGATTTTCCGGCAGCGGCTCTGGCACCGACTTCACCCTGAC
CATCAGCTCCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCAAGCAGTACTGGAACACCC
CCTTCACCTTCGGACAGGGCACCAAGGTGGAAATCAAGAGAGCGGCCGCTGGCGCCCCTGT
GCCTTATCCTGATCCCCTGGAACCTAGAGGCGGCAGCCACCACCACCATCACCACTGATGA 
 
Figure 2-2 pCXCL12 Trap DNA sequence and vector map  
 
The coding sequences of the CXCL12-binding VH and VL domains derived from 4LMQ were used for 
assembly of the trap gene. The final sequence for the CXCL12 trap codes for a signaling peptide, VH 
domain, a flexible linker, VL domain, E tag, and His(6×) tag, respectively. The complete cDNA was cloned 
into pCDNA3.1 between Nhe I and Xho I sites and the accuracy was confirmed by DNA sequencing. 
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Figure 2-3 Binding affinity and effect of engineered CXCL12 trap protein on in vitro cellular 
migration and invasion  
 
A) The binding affinity between CXCL12 trap and CXCL12 measured by Bio-Layer Interferometry, where 
CXCL12 was immobilized on the AR2G biosensor and the binding kinetics were measured against 
increasing concentrations of CXCL12 trap (0, 125, 250, and 500 nM) to determine the kon and koff rates 
depicted by the tracing of signal intensities versus time. The dissociation constant (Kd) was calculated to be 
4.0 ± 0.4 nM after determining the on and off rate depicted. B) The Chemotaxis Migration Assay Kit (EMD 
Millipore) with a pore size of 8 µm was used to investigate inhibition of cellular migration. Analysis of CT-
26(FL3) cell migration towards a concentration gradient of CXCL12 (10 nM) in the presence of CXCL12 
trap (60, 120, 240, or 360 nM). A positive control CXCL12 Ab (6, 12, or 24 nM) was also used. The 
engineered CXCL12 trap was found to have one-half maximal inhibition [ND50] against biologically active 
CXCL12 (10 nM) at a concentration of 120 nM. C) Invasion Assay Kit (EMD Millipore) with a pore size 
of 8 µm and ECMatrix was used to analyze the increase in CT-26(FL3) cell invasion towards a 
concentration gradient of CXCL12 (10 nM) in the presence or absence of CXCL12 trap (120 or 240 nM) 
or control CXCL12 Ab (24 nM). Data were expressed as mean ± s.d., calculated from samples performed 
in triplicate and as a percentage of untreated (no CXCL12 or treatment protein) control. Cell migration and 
invasion were determined through cell collection, lysis, and quantification by luciferase bioluminescent 
analysis. Statistically significance is indicated in graph compared to the control containing CXCL12 (10 
nM) in the feeder (lower) plate void of CXCL12 trap or Ab. N.S. denotes, not significant. 
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Figure 2-4 Nanoparticle characterization by TEM and DLS  
 
(A) LCP core containing pDNA/mc-CR8C peptide (B) Final galactose-LCP containing pDNA/mc-CR8C, 
with negative uranyl acetate stain (C) Dynamic light scattering (DLS) analysis of final galactose-LCP 
containing pDNA/mc-CR8C, yielding 45 nanometers in diameter and Zeta potential of +10.0. Number, 
volume, and intensity weighted size distribution illustrates two particle distribution. The smaller population 
(~45 nm) is the desired LCP particles, and the larger population (~350 nm) is due to excess DOTAP and 
cholesterol which form liposomes after thin-film hydration, yielding a Z-average of ~236±32 nm; n=6. (D) 
The stability of the LCP over time in a 10% serum solution was measured through DLS. The LCP was 
suspended in 10% serum solution and incubated at 37°C. The z-average was recorded over 24 hours to 
observe any protein/LCP aggregation indicated by increased z-average. Data were expressed as mean ± s.d., 
calculated from samples ran in triplicate. The z-average (~30 nm) was consistent over the 24 hours, yielding 
no significant increase in the z-average, indicating minimal formation of protein/LCP aggregates. 
 
 48 
 
 
Figure 2-5 Pharmacokinetic and organ biodistribution analysis of galactose-LCP-pCXCL12  
Trap/mcCR8Cwith 177Lu incorporated into the LCP core  
 
Approximately 250,000 counts were administered into the mice by tail vein injection. (A) Blood samples 
collected via tail vein cut were collected, weighed, and measured for radioactive counts to determine the 
percentage of injected dose (%ID) remaining in circulation. A biphasic distribution is observed, yielding 
T1/2α and T1/2β of 20 min and 1,054 min respectively. (B) LCP biodistribution/organ accumulation was 
measured at 16 hours after tail vain injection (a time when blood radiation counts reached background 
signal). Approximately 40-50% of the injected dose per gram of tissue was found to accumulate in the liver. 
Data were expressed as mean ± s.d., calculated from samples ran in triplicate. 
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Figure 2-6 Transient liver-specific expression of pGFP and engineered pCXCL12 trap  
 
A) Microscopy analysis of GFP expression in major LCP-accumulating organs. The liver sections 
demonstrate transient expression for at least 4 days after final injection (10 µg every other day x3. Scale 
bar: 250 μm. Data were expressed as mean ± s.d., calculated from at least triplicated samples and reported 
as a fluorescent intensity quantified by Image J software. N.S. denotes no significance, N.D. denotes under 
detection limit, p-values represent significance to untreated sample. Scale bar 250 μm.  B) His(6×)-tag 
ELISA and Western blot analysis were conducted to determine the organ distribution/expression of the 
pCXCL12 trap in all major LCP-accumulating organs and serum. Doses were escalated from 2.0, 10.0, or 
20.0 µg pDNA administered via tail vein. C) Western blot analysis of organs show CXCL12 trap expression 
through use of His(6×) mAb.  The expression is transient and only lasts for at least 4 days and no longer 
than 8 days after the final injection (10 µg every other day x3). Total protein concentrations were 
determined by BCA and 50 µg of total protein was loaded per well/lane. Trap protein was detected at 28.6 
kDa, as confirmed by a protein standard ladder, consistent with the theoretical value. GAPDH was used as 
a loading control, except in the serum samples, where GAPDH is not present.  Data were expressed as mean 
± s.d., calculated from samples run in triplicate and shown as a fold increase compared to untreated control. 
N.S. denotes no significance, N.D. denotes under detection limit. The p-values of groups compared to 
corresponding untreated control are displayed in graphs. 
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Figure 2-7 Transient hepatocyte-specific expression of pGFP on day 4 after final pGFP LCP injection  
 
Microscopy analysis of GFP expression in hepatocytes. The liver sections demonstrate the transient nature 
of this treatment, where expression is found to last 4 days after final injection (10 µg every other day x3), 
with the hepatocytes being the major GFP-positive cell population. The majority of GFP-positive cells 
correspond to binucleated hepatocytes with square morphology. The DAPI nuclear (blue) and phalloidin 
actin (red) stains are shown in merged images.  
 
 
 
 
 
 
 
 
 51 
 
 
Figure 2-8 Biological trapping of endogenous CXCL12 and immune cell recruitment  
 
A) Endogenous CXCL12 expression in paraffin-embedded sections of liver tissues from BALB/c mouse 
models of colorectal cancer sacrificed 10 days after the final treatment injection and control healthy livers 
[healthy (No CRC)]. Immunofluorescent stain for CXCL12 (red), along with DAPI nuclear stain (blue). 
Five groups were studied, including healthy (No CRC), untreated (PBS), pGFP LCP control (10 µg every 
other day x 3), pTrap LCP (10 µg), pTrap LCP (10 µg every other day x 3). All data were expressed as 
mean ± s.d., calculated from samples run in triplicate and reported as fluorescent intensity. N.S. denotes no 
significance, N.D. denotes under detection limit. The p-values of individual groups compared to 
corresponding untreated control are displayed in graphs. Scale bar: 250 μm. B) Additional sections were 
stained to determine the recruitment of immune cells to the liver, including immunosuppressive anti-
inflammatory MDSCs [CDllb+(Green)/GR1+(Red)] and T-reg [CD4+(Green)/Foxp3+(Red)] as well as the 
CD8+ T cell population (Green).  Four groups were studied, including healthy (No CRC), untreated 
(Tumor), untreated (Stroma), and pTrap LCP (10 µg every other day x 3). Trichrome staining is also shown 
to distinguish normal and diseased liver. White arrows indicate metastatic lesions. All data were expressed 
as mean ± s.d., calculated from samples run in triplicate and reported as fluorescent intensity. N.S. denotes 
no significance, N.D. denotes under detection limit. The p-values of individual groups compared to 
corresponding untreated control are displayed in graphs. Scale bar: 250 μm 
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Figure 2-9 Endogenous CXCL12 in major organs of mice (without CRC) and in the liver of a CRC 
mouse 
 
Endogenous CXCL12 expression in different organs from BALB/c mice. The images show 
immunofluorescent staining against CXCL12 (red), along with DAPI nuclear stain (blue). Data were 
expressed as mean ± s.d., calculated from at least triplicated samples and reported as a fluorescent intensity. 
N.S. denotes no significance, N.D. denotes under detection limit, p-values represent significance of the 
difference relative to the liver sample. Scale bar 250 μm.   
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Figure 2-10 Total mouse tumor burden on day 24 after cecal inoculation  
 
Mice were inoculated with 2x106 CT-26 F3 RFP/Luc cells into the cecum wall. Treatment consisting of 10 
µg pDNA was administered through tail vein IV on days 10, 12, and 14. Groups included PBS (untreated; 
n=7), pGFP DNA LCP (10 µg every other day x 3; n=6), and pCXCL12 trap LCP (10 µg every other day 
x 3; n=7). Progression of tumor mass was followed by administration of 200 µl luciferin (10 mg/ml) IP. 
Luciferase bioluminescent imaging was performed 10 min after administration of luciferin.  
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Figure 2-11 Decreased incidence of liver metastasis after pCXCL12 Trap LCP treatment  
 
A) Mice were inoculated with 2x106 CT-26(FL3) RFP/Luc cells into the cecum wall. Treatment schedule 
is shown above. Treatment, 10 µg (0.5 mg/kg) pDNA, was administered through the tail vein IV on days 
10, 12, and 14. Groups included PBS (untreated; n=7) and pGFP LCP (10 µg every other day x 3; n=6), as 
well as pCXCL12 Trap LCP (10 µg every other day x 3; n=7). Progression of overall tumor mass was 
followed by administration of 200 µl luciferin (10 mg/ml) IP. Luciferase bioluminescent imaging was 
recorded 10 min after administration of luciferin. Whole mouse and liver tumor burden were recorded. All 
data were expressed as mean ± s.d., and reported as bioluminescent intensity. N.S. denotes no significance, 
N.D. denotes under detection limit. The p-values of individual groups compared to corresponding untreated 
control are displayed in graph.  B) Total organ tumor burden of untreated (n=3) and therapeutic pCXCL12 
Trap LCP (n=4) groups. Quantification of tumor burden in organs was performed with IVIS/Kodak 
software. All data were expressed as mean ± s.d., and reported as bioluminescent intensity. N.S. denotes no 
significance, N.D. denotes under detection limit. The p-values of individual groups compared to 
corresponding untreated control are displayed in graph.  C) Paraffin-embedded liver sections were stained 
with trichrome. Large tumor burden (indicated by black arrows) and cirrhosis/fibrosis (blue stain, collagen) 
are clearly seen in the PBS (untreated) and pGFP LCP treatment groups. The pCXCL12 Trap LCP treated 
livers have normal healthy liver morphology and no detectable metastatic burden. Scale bar is 250 µm.  
Collagen quantification in liver section was recorded. All data were expressed as mean ± s.d. N.S. denotes 
no significance, N.D. denotes under detection limit. The p-values of individual groups compared to 
corresponding untreated control are displayed in graph. 
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Figure 2-12 Decreased incidence of liver metastasis and enhanced T cell killing after pCXCL12 trap 
LCP therapy  
 
A) Mice were inoculated with 2x106 CT-26(FL3) RFP/Luc cells into the cecum wall. Treatment, 10 µg (0.5 
mg/kg) pDNA, was administered through tail vein IV on days 10, 12, and 14. Groups included PBS 
(untreated; n=5) and pCXCL12 Trap LCP (10 µg every other day x 3; n=5) with either anti-Lyt2.2 or isotype 
IgG control administrated on days 8 and 10 IP (400 µg, 20 mg/kg). Inoculation and treatment schedule/dose 
and liver tumor mass on day 21 are shown above. Mice were administered 200 µl (10 mg/ml) luciferin IP. 
After 5 min, mice were euthanized and livers were extracted, rinsed in PBS, and placed in a solution of 
luciferin (1 mg/ml). The bioluminescent images were recorded using IVIS kinetic with Kodak camera. 
Quantification of tumor burden in the liver was performed with IVIS/Kodak software. Data were expressed 
as log-transformed mean, normalized ± s.e. N.S. denotes no significance, N.D. denotes under detection 
limit. The p-values of individual groups compared to corresponding untreated control are displayed in graph. 
ROI = region of interest. 
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Figure 2-13 Decreased incidence of 4T1 liver metastasis and increased survival after pCXCL12 Trap 
LCP treatment  
 
A) The figure shows the inoculation and treatment schedule and doses, as well as bioluminescent signal 
detection and tumor burden quantification 7 days after inoculation. Treatment groups included PBS 
(untreated; n=5), pGFP LCP/anti-CD8 (n=5), pTrap LCP/anti-CD8 (n=5), pTrap LCP/Isotype IgG (n=5).  
Data were expressed as log-transformed mean, normalized ± s.e. N.S. denotes no significance, N.D. denotes 
under detection limit. The p-values of individual groups compared to corresponding untreated control are 
displayed in graph. ROI = region of interest. B) Flow cytometry analysis of tumor burden and quantification 
on day 10 (n=3 per group). Gating consists of GFP positive tumor cells (P3) versus non-GFP positive cells 
(P4) Data were expressed as mean, normalized ± s.d. N.S. denotes no significance, N.D. denotes under 
detection limit. The p-values of individual groups compared to corresponding untreated control are 
displayed in graph. C) Kaplan-Meier survival curve including all 4 treatment groups (n=5 per group).  
Survival was determined by evaluating mouse weight, activity, and quality of life. N.S. denotes no 
significance, N.D. denotes under detection limit. The p-values of individual groups compared to 
corresponding untreated control are displayed in graph. 
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Figure 2-14 Comparison of therapeutic strategies for reducing incidence of colorectal cancer (HT-29) 
liver metastasis  
 
A) The timeline at the top shows the inoculation and treatment schedule and dosing for the HT-29. 
Treatments were administered every other day on days 0-16, through tail vein IV. Treatment groups 
included PBS (untreated; n=5), pGFP LCP (10 µg, 0.5 mg/kg pDNA; n=5), pTrap LCP (10 µg, 0.5 mg/kg 
pDNA; n=5), free CXCL12 trap protein (10 µg, 0.5 mg/kg protein; n=5), and AMD3100 (100 µg, 5.0 mg/kg; 
n=5).  B) Tumor burden analysis and quantification on day 36 (n=5 per group). Liver metastasis burden 
was quantified by resection and weighing of tumor nodules (in mg). Image of liver from each treatment 
group with metastatic burden shown, white arrows indicate metastatic lesion).  Survival was determined by 
evaluating mouse weight, activity, and quality of life. Data were expressed as individual data points with 
mean ± s.d. N.S. denotes no significance, N.D. denotes under detection limit. The p-values of individual 
groups compared to corresponding untreated control are displayed in graph. 
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Figure 2-15 Toxicological analysis  
 
ALT, AST, creatinine, and BUN measurements and blood leukocyte cell counts 24 hours after final 
treatment with PBS (untreated), 10 µg pGFP LCP every other day x 3, 10 µg pCXCL12 Trap LCP every 
other day x 3, or free CXCL12 trap protein (20 µg every other day x 3), in which mice were sacrificed on 
days 1, 7, and 14 after final administration. All data were expressed as mean ± s.d. from samples run in 
triplicate. N.S. denotes no significance, N.D. denotes under detection limit. The p-values of individual 
groups compared to corresponding untreated control are displayed in graph.  B) Trichrome histology 
sections of different organs 24 hours after final treatment with PBS (untreated), 10 µg pGFP LCP every 
other day x 3, 10 µg pCXCL12 Trap LCP every other day x 3, or free CXCL12 trap protein (20 µg every 
other day x 3), in which mice were sacrificed on days 1, 7, and 14 after final administration. All trichrome 
histology sections show no toxicity in any major organ including: heart, lung, spleen, kidney, and liver. 
Scale bar =100 µm. 
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Figure 2-16 Diagram of the proposed pCXCL12 Trap LCP Mechanism   
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3. Chapter 3: Development and Investigation of Phosphorylated Adjuvants 
Co-encapsulated with a Model Cancer Peptide to Overcome the Immune 
Tolerance in a Murine Orthotopic Colorectal Liver Metastasis Model3 
3.1 Overview 
The lipid calcium phosphate nanoparticle is a versatile platform capable of encapsulating a 
wide range of phosphorylated molecules from single nucleotides to pDNA. The use of this 
platform has shown great success as an immunotherapeutic vaccine carrier, capable of delivering 
co-encapsulated phosphorylated adjuvants and peptides. Three potent vaccine formulations were 
investigated for anti-cancer efficacy. The phosphorylated adjuvants, CpG, 2’3’cGAMP, and 
5’pppdsRNA were co-encapsulated with a model phosphorylated tumor specific peptide antigen 
(p-AH1-A5). The anti-cancer efficacy of these adjuvants was assessed using an orthotopic 
colorectal liver metastasis model based on highly aggressive and metastatic CT-26 FL3 cells 
implanted into the cecum wall. The results clearly indicate that the RIG-1 ligand, 5’pppdsRNA, 
co-encapsulated with the p-AH1-A5 peptide antigen greatly reduced the growth rate of the 
primary colon cancer as well as arrested the establishment of liver metastasis in comparison to 
the other adjuvant formulations and unvaccinated controls. Further evaluation of the immune cell 
populations within the primary tumor confirms the ability of the 5’pppdsRNA adjuvant to boost 
                                                   
3 This chapter previously appeared as an original research article in Vaccine. The original citation is as 
follows: Goodwin T, Huang, L. Investigation of Phosphorylated Adjuvants Co-encapsulated with a 
Model Cancer Peptide Antigen for the Treatment of Colorectal Cancer and Liver Metastasis, Vaccine. 
2017. 
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the adaptive CD8+ T-cell population, while not inciting increased populations of immune 
suppressive cell types such as T-regulatory cells or myeloid derived suppressor cells. 
Furthermore, this is the first study to investigate the anti-cancer efficacy of a specific RIG-1 
receptor ligand, 5’pppdsRNA, alongside more established TLR 9 (CpG) and STING 
(2’3’cGAMP) adjuvants in a cancer vaccine. The 5’pppdsRNA vaccine formulation can be a 
potent immunotherapy, especially when combined with agents that remodel the immune 
suppressive microenvironment of the tumor. 
3.2 Introduction  
Colorectal cancer is one of the major cancers for which new immune-based treatments are 
currently in development. Colorectal cancer is the third most common type of cancer in the United 
States, and is the second most deadly. In 2016 over 90,000 new cases of colon cancer, and close 
to 40,000 new cases of rectal cancer were reported in the US alone. Furthermore, it is estimated 
that nearly 50,000 patients will succumb to colon cancer in the US, and over 700,000 worldwide 
this year. Although screening and preventative measures has aided in early treatment to prolong 
survival rates, only 40% of colorectal cancers are diagnosed at a localized stage. , the 5-year 
survival rate drastically decreases from 90% at the local stage, to only 13% once the cancer has 
spread to distant organs such as the liver 60.  
Cancer immunotherapy is one such strategy to treat colorectal cancer. This strategy is based 
on manipulating the hosts innate and adaptive immune response in such a way that the host 
recognizes and resists cancer progression. Numerous published reports have shown that 
immunotherapy is a promising approach for the treatment of colorectal cancer. One such report 
from Ohtani et al., demonstrated that the presence and location of CD8+ killer T cells within the 
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tumor microenvironment correlated with better outcomes in colon cancer patients 61. Furthermore, 
over the decades the development and understanding of unique adjuvants that elicit robust immune 
responses through a specific mechanism has grown substantially. These adjuvants have seen 
increased use in cancer vaccine formulations to elicit desired immune responses against cancers. 
The most reported adjuvants over the past two decades in the field consist of CpG and poly(I:C), 
which targets toll-like receptors (TLRs), located on the cell membrane or endosome 62. More 
recently, new generations of adjuvants such as 2’3’cGAMP and 5’pppdsRNA have been studied 
for targeting the cytoplasmic receptors, stimulator of interferon gene (STING) and retinoic acid-
inducible gene 1 (RIG-1) 63-65. The unique mechanism by which these adjuvants elicit an immune 
response and the type of immune response elicited have been studied in detail 63 66-70.  
Cancer vaccines for the treatment of colorectal cancer is promising. Several tumor associated 
antigens such as carcinoembryonic antigen (CEA), mucin 1 (MUC1), human epidermal growth factor 
receptor 2 (HER2) and NY-ESO-1 have been identified 34. Many clinical trials using these antigens 
have reached late phase II and III studies 35. However, the mechanism by which the immune cells are 
activated, the type of activation, and the response provoked by the adjuvant presented to the immune 
cells is not entirely clear. In the present study, co-encapsulation of one of three distinct adjuvants, CpG, 
a TLR9 ligand, 2’3’cGAMP, a STING ligand, or 5’pppdsRNA, a RIG-1 ligand was investigated. These 
distinct adjuvants were co-encapsulated with a model mouse colon cancer peptide antigen (p-AH1-A5) 
into a lipid calcium phosphate (LCP) nanoparticle 71. Antigen specific interferon gamma (INF-γ) 
response and cytotoxic T-lymphocyte (CTL) killing were studied. More importantly, identification of 
which adjuvant could help to break the cancer immune tolerance, and reduce tumor growth and liver 
metastasis was determined. Furthermore, the dependence of the therapeutic effect on the recruitment 
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of CD8+ T-cells in the tumor as well as reduced populations of the immune suppressive T-regulatory 
(T-reg) cells and myeloid derived suppressor cells (MDSCs) was also elucidated.  
3.3 Material and Methods 
3.3.1 Materials 
Dioleoylphosphatydic acid (DOPA) and 1,2-dioleoyl-3-trimethylammonium-propane 
chloride salt (DOTAP) were purchased from Avanti Polar Lipids (Alabaster, Al). 1,2-Distearoryl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000)] ammonium salt 
(DSPE–PEG) and DSPE-PEG-NHS were purchased from NOF (Tokyo, Japan). Cholesterol was 
purchased from Sigma-Aldrich (St. Louis, MO). DSPE–PEG–mannose was synthesized per the 
previously established protocol in the lab. Peptides, purity >98%, β-gal, AH1(SPSYVYHQF), and 
phosphoserine-modified-AH1-A5 ((pS)(pS)SPSYAYHQF) peptide were synthesized by Peptide 
2.0 (Chantilly, VA). CpG ODN 1826 (5′-TCCATGACGTTCCTGACGTT-3′) was ordered from 
Sigma-Aldrich. 2’3’cGAMP and 5’pppdsRNA were ordered from Invivogen (San Diego, Ca). 4-
Dimethylaminopyridine and other chemicals were purchased from Sigma-Aldrich if not noted 
otherwise.  
3.3.2 Mice and antibodies 
Six- to eight-week old female BALB/c mice were obtained from Charles River (Bethesda, 
MD). Animals were raised in the Center for Experimental Animals (an AAALAC accredited 
experimental animal facility) in the University of North Carolina (UNC) at Chapel Hill. All animal 
handling procedures were approved by the UNC at Chapel Hill's Institutional Animal Care and 
Use Committee. Primary fluorescent antibodies used for immunofluorescent microscopy and flow 
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cytometry analysis include: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD8α, 
FITC-conjugated anti-mouse CD4, PE-conjugated anti-mouse FOXP3, FITC-conjugated anti-
mouse CD11b, and PE-conjugated anti-mouse Gr were obtained from BD Biosciences (San Jose, 
CA). Analysis was performed on a FACSCaliber flow cytometer and analyzed using Cell Quest 
software (BD Biosciences) 
3.3.3 Study design 
This was a preclinical study to assess the efficacy and safety of several adjuvant based 
peptide vaccines delivered via a non-viral vector to elicit a therapeutic immune response. It is 
hypothesized that although adjuvants may stimulate a robust pro-inflammatory immune response, 
detected via IFN-γ and CTL assays, it is necessary to compare in a side by side efficacy study in 
an aggressive orthotopic model. This hypothesis was tested through an established orthotopic 
syngeneic murine colorectal liver metastasis model. The number of mice used for the in vivo 
experiments are outlined in the figure legends. Grouping for tumor experiments was accomplished 
through measuring the tumor burden via bioluminescence techniques, ranking, and distributing 
equally. Additional study design details are also included in the statistical analysis and 
supplemental information section.  
3.3.4 CT-26(FL3) (RFP/Luc) culture 
CT-26(FL3) cells were obtained from Dr. Maria Pena’s lab at the University of South 
Carolina 44, and cultivated in Dulbecco’s Modification of Eagle’s Medium (DMEM) with 4.5 g/L 
glucose (Gibco) supplemented with 10 % fetal bovine serum (FBS) (Gibco) and 1 % 
Penicillin/Streptomycin (Pen/Strep, Gibco) at 37 °C and 5 % CO2 in a humidified atmosphere. 
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Lentivirus transfection of cell line was performed in which CT-26(FL3) cells were incubated in 
media containing lentivirus.  Cells stably transfected with the vector carrying the mCherry red 
fluorescent protein (RFP), firefly luciferase (Luc), and the puromycin resistance gene were 
analyzed using a fluorescence microscope. Stably transfected CT-26(FL3) cells were selected in 
the presence of puromycin.    
3.3.5 Preparation of LCP loaded with pDNA  
LCP was prepared using a modified protocol 72. Two separate microemulsions (60 mL each) 
were prepared of Igepal 520 and cyclohexane (3:7 v/v) and placed under stirring. A solution of p-
AH1-A5 and adjuvant (10:1 ratio) corresponding to equal encapsulation efficiency (500 µL total 
volume of 2 mg/mL p-AH1-A5 and 200 µg/mL adjuvant) solution was prepared. Following mixing 
of peptide and adjuvant, the solution was pipetted into 1,800 μL of 2.5 M CaCl2 and pipetted until 
thoroughly mixed. No aggregation was visible. Immediately add and allow to stir for 5 min into 
the oil solution to form a microemulsion. A (NH4)2HPO4 solution (1,800 μL, 50 mM) was also 
prepared and added to the other oil solution to form a microemulsion. The microemulsion 
containing (NH4)2HPO4 was added to the microemulsion containing the peptide/adjuvant/CaCl2. 
This solution was stirred for 5 min before addition of 1,400 μL of 20 mM DOPA (in CHCl3). After 
addition of DOPA the microemulsion was left to stir for an additional 30 min. An equal volume 
of 100 % EtOH (120 mL) was added to disrupt the emulsion. The mixture was centrifuged at 
10,000g for 20 min. After decanting the supernatant, the precipitate was washed, including vortex 
and sonication, twice thereafter with 100% EtOH to remove traces of Igepal and/or cyclohexane. 
The precipitate was then suspended in CHCl3. This solution was centrifuged at 12,000 rpm for 10 
min for the removal of large aggregates, and the supernatant containing the LCP “cores” (Peptide 
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and adjuvant entrapped within a calcium phosphate nanoprecipitate, supporting and surrounded by 
a lipid monolayer of DOPA) was recovered. A single batch typically produces approximately 45 
mg of cores. The ratio of cores to outer leaflet lipids for optimal final particle formulation was 
found to be 4.5 mg core:  250 µL DOTAP (20 mM): 250 µL Cholesterol (20 mM): 200 µL DSPE-
PEG2000 (20 mM). Therein, 35 mol % DOTAP, 35 mol % cholesterol, and 30 mol % DSPE-
PEG2000 (or 25 mol % DSPE-PEG and 5 mol % DSPE-PEG-Mannose) were utilized as outer 
leaflet lipids. Preparation of final particles for injection followed formation of lipid film through 
drying off chloroform with nitrogen gas, followed by resuspension in 5 % aqueous glucose solution 
and sonication. Zeta potential and particle size of LCP were measured using a Malvern ZetaSizer 
Nano Series (Westborough, MA). TEM images of LCP were acquired using a JEOL 100CX II 
TEM (JEOL, Japan). 
3.3.6 Characterization of LCP loaded with p-AH1-A5 and adjuvant  
Entrapment was characterized through several methods. Firstly, fluorescently labelled CpG 
and 5’pppdsRNA was purchased via sigma Aldrich. Cy3-adjuvant was formulated into the LCP 
cores, after which recovery was assessed via fluorescence spectrometry and standard curve of each 
adjuvant. Encapsulation of the 2’3’cGAMP was characterized via UV spectroscopy, in which the 
LCP cores were collected, dried, and suspended in acetic acid buffer (pH=4) to achieve core lysis. 
The solution was then centrifuged and the supernatant was collected and analyzed via UV 
spectroscopy to determine absorbance value of 2’3’cGAMP at 257 nm wavelength. Standard 
curves were generated using blank LCP cores, along with known concentrations of 2’3’cGAMP 
and used to calculate encapsulation efficiency. 125I-labeled p-AH1-A5 was prepared via use of an 
Iodination kit in which 125I was used to mark the tyrosine amino acid in p-AH1-A5. The cores 
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were prepared and the encapsulation was measured via γ-counter. The final LCP cores 
encapsulated ~70% of 125I-labelled peptide. 
3.3.7 In vivo biodistribution of mannose-targeted LCP vaccine formulation 
Quantitative biodistributions were determined via co-encapsulation of adjuvant with 125I-
labelled p-AH1-A5. 125I-labeled p-AH1-A5 cores were prepared as described above. Final LCP 
was produced through desiccation of a mixture of free lipids and cores and rehydration via 5 % 
aqueous glucose solution. Such methods have been utilized previously to accurately determine 
LCP biodistribution 72. 8-week-old BALB/c female mice (3 mice utilized for each group) were 
injected individually (0.2 mL, balanced in osmolarity with the addition of sucrose) with LCP at 
1.25 mg peptide/kg, corresponding to a dose of 1 × 104 cpm of 125I. For biodistribution analysis, 
mice were euthanized at 4, 16, and 48 h after the administration of LCP. The major organs and 
lymph nodes were collected (3 mice utilized for each time point). Radioactivity in the tissues were 
measured using a γ-counter.  
3.3.8 IFN-γ ELISPOT assay  
Mice were vaccinated with corresponding treatment groups. Seven days post vaccination, 
the spleen and proximal lymph node were harvested and made into single-cell suspensions in a 
sterile cell-culture hood. Cells were seeded at 1×105 per well in a capture antibody coated 96-well 
plate. The single-cell suspensions were then cocultured with either 5 µM of β-gal or AH1 peptide 
at 37 °C for 18 h. Cells were subsequently removed by several wash steps. The production of IFN-
γ was measured by addition of detection antibody followed by enzyme conjugate magnification. 
Red dots signals were developed with a BD ELISPOT substrate set and calculated manually. 
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3.3.9 In vivo CTL Assay  
A CTL response assay was performed seven days following a single vaccination. The 
methods followed the referenced method with slight modifications 72. Briefly, splenocytes from 
naive BALB/c mice were collected from the spleens. The splenocyte cell suspensions were 
immediately pulsed with either 10 µM of control peptide (β-gal) or tumor-associated antigen 
peptide (AH1) in complete RPMI 1640 medium at 37 °C for 1.5 h. Β-gal peptide–pulsed and AH1 
peptide–pulsed splenocytes were then labeled with 0.5 and 5 µM of carboxyfluorescein 
succinimidyl ester (CFSE), respectively for 15 min. Splenocytes were analyzed for CFSE staining 
by Flow cytometry, and high and low stained splenocytes were mixed to insure a 1 to 1 ratio of 
high and low splenocyte mixture. The mixture was then IV injected into the groups of vaccinated 
mice. After 16 h, splenocytes were collected again from the vaccinated or control mice and 
subjected to flow cytometry analysis. The numbers of CFSElow cells and CFSEhigh cells were 
recorded and the in vivo AH1-specific lysis was calculated. 
3.3.10 Flow cytometry 
Tumor cells and splenocytes were made into single-cell suspensions. Immune lymphocytes 
were quantitatively analyzed by flow cytometry via immunofluorescent staining. Tissues were 
harvested and digested with collagenase A and DNase at 37 °C for 45 min. After red blood cell 
lysis via addition of RIPA buffer, cells centrifuged at 2,000 g for 10 min. Following centrifugation, 
samples were washed and resuspended in 1 mL of phosphate-buffered saline. Cells were counted 
and diluted to 5×106 cells/mL. Cells were then stained by addition of the fluorescent-conjugated 
antibodies CD8, CD4, CD11b, GR-1. For intracellular FOXP3 staining, the cells were permeated 
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via penetration buffer (BD, Franklin Lakes, NJ) following the manufacturer's instructions. 
Following staining cells were fixed and analyzed via FACS.  
3.3.11 Immunohistochemistry 
Histology and immunohistochemistry were performed on paraffin-embedded tumors. All 
paraffin-embedded tissue was resected, rinsed in PBS, and placed in 4 % paraformaldehyde for 48 
h at 4 °C. Following 4 % PFA, tissues were rinsed in water and placed in 70 % ethanol solution 
until paraffin-embedded. Immunofluorescence staining was processed through deparaffination, 
antigen retrieval, permeabilization, and blocking in 1 % bovine serum albumin at room 
temperature for 1 h. Primary antibodies conjugated with fluorophores (BD) were incubated 
overnight at 4 °C and the nuclei were counterstained with 4',6-diamidino-2-phenylindole 
containing mounting medium (Vector Laboratories, Burlingame, CA). All antibodies were diluted 
after optimization. Images were taken using fluorescence microscopy (Nikon, Tokyo, Japan). A 
minimum of three randomly selected microscopic fields were quantitatively analyzed using Image 
J software. 
3.3.12 Toxicity analysis  
Mice were treated with p-AH1-A5 adjuvant LCPs, blank loaded LCP, or PBS (1.25 mg 
peptide/kg and 0.125 mg/kg adjuvant x 2) (three mice for each group) and analyzed for toxicity 1, 
7, and 14 days post final injection. Serum was obtained from the mice via cardiac puncture and 
centrifugation. Hepatic and renal damage was assessed by measuring the levels of AST, ALT, 
creatinine and BUN in the serum samples. Blood cell levels, including white blood cells, 
lymphocytes, granulocytes, and monocytes were measured with whole blood analysis. These 
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measurements were quantified by the Animal Clinical Chemistry and Gene Expression 
Laboratories at UNC Chapel Hill.  
3.3.13 Orthotopic allografting in mice 
Sub-confluent CT-26 FL3 (RFP/Luc) cells were harvested and washed in phosphate 
buffered saline (PBS) just prior to cecal. Eight-week-old male BALB/c or nude mice were 
anesthetized by inhalation of 2% isoflurane and placed in supine position. For cecum inoculation, 
a midline incision was made to exteriorize the cecum. Using an insulin-gage syringe, 2×106 CT-
26(FL3) cells in 25 µL were injected into the cecum subserosal. Light pressure was applied to the 
injection site to stop any leaking of injection that may occur, followed by sterilization with 70 % 
alcohol to kill cancer cells that may have leaked out. The cecum was returned to the peritoneal 
cavity and the incision site was sutured 3.  
3.3.14 In vivo luciferase imaging of whole animal 
Luciferase imaging of tissue and animals was performed as follows in which D-luciferin 
of 1.0 mg/10g body weight was injected intra-peritoneally into mice. Following 10 min post 
administration, luciferase imaging (IVIS-Kinetic) was applied on the whole-mouse. Imaging and 
quantification were performed at the UNC Biomedical Research Imaging Center (BRIC) using the 
IVIS kinetic optical imaging system. Quantification of bioluminescent signal was reported as 
either the raw average intensity or fold change.  
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3.3.15 In vivo colorectal liver metastasis efficacy study   
Mice were inoculated with 2x106 CT-26(FL3) RFP/Luc cells into the cecum wall six days 
prior to vaccination. Vaccination was initiated on days 0, and a boost was administered on day 6 
via subcutaneous injection (n = 6-10). Progression of tumor mass was followed by administration 
of 200 µL luciferin (10 mg/mL) IP. Luciferase bioluminescent imaging was recorded 10 min after 
administration of luciferin. On day 15, mice were imaged, sacrificed, and organs were then 
extracted. Images of livers were recorded and metastatic lesions were quantified via counting.  
2.5.16 Statistical analysis  
Data were expressed as the mean ± standard deviation (SD). Statistical analysis was 
performed via PRISM software using Student t-test when only two value sets were compared, and 
one-way analysis of variance (ANOVA) with a Dunnette’s test for post hoc analysis when the data 
involved three or more groups. *, **, *** denotes p < 0.05, 0.01, and 0.001, respectively, and was 
considered significant and documented on figure or figure legend. In all statistics, the groups are 
compared against the PBS control. More detailed methods are provided in the supplemental 
information  
3.4 Results  
3.4.1 Characterization of formulated LCP nanoparticles containing phosphorylated 
adjuvant and antigen 
Xu et al. first reported the formulation and delivery of the mannose targeted LCP co-
encapsulating a phosphorylated peptide antigen and CpG adjuvant 72. A graphical illustration of 
the LCP containing the phosphorylated peptide and adjuvant is depicted in Figure 3-1A. The core 
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structure can be visualized under transmission electron microscopy (TEM) (Figure 3-1B). The 
DOPA monolayer surrounding the CaP core allows for the addition of the cationic outer leaflet 
lipids (1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), helper lipid cholesterol, and 
mannose conjugated to 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-
[succinyl(polyethylene glycol)-2000 (DSPE-PEG2000) to assist in dendritic cell uptake, 
producing the “final” LCP particles (40–60 nm in diameter, shown in Figure 3-1B/C). In this 
report the hydrodynamic diameter and the surface charge of the LCP particles were found via 
dynamic light scattering zetasizer analysis to be approximately 35 nm and 10 mV, respectively 
(Figure 3-1C). The p-AH1-A5 peptide encapsulation efficiency was found to be approximately 
70 %, while the CpG, 2’3’cGAMP (cGAMP), and 5’pppdsRNA (dsRNA) corresponded to 56 %, 
32 %, and 76 % when co-encapsulated with p-AH1-A5. All adjuvants were encapsulated at a 1:10 
ratio of adjuvant to peptide by weight. The organ distribution was determined through 
incorporation of 125I radioisotope onto the tyrosine of the p-AH1-A5. The LCP particles containing 
the 125I p-AH1-A5 were injected subcutaneously into the left flank of healthy BALB/c mice. The 
organ distribution profile studies demonstrate that approximately 20-30 % of the ID/g of the 
mannose-LCP nanoparticles distribute to the proximal lymph nodes, while approximately 5 % of 
the ID/g is found in distal lymph nodes and spleen (Figure 3-1D).  
3.4.2 In vivo immune response profile of LCP vaccines (IFN-γ ELISPOT/Cytotoxic T-
Lymphocyte Assay)   
Investigation into the potency in which all three vaccine formulations containing the 
corresponding adjuvant could elicit a robust immune response was assayed via IFN-γ ELISPOT 
and CTL. The IFN-γ which is produced predominantly by cytotoxic T cells is reported to mediate 
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tumor rejection in colon cancer models. Therefore, investigation into the IFN-γ production by 
lymphocytes 7 days post vaccination was analyzed using a BD ELISPOT assay system. It was 
found that 0.125 mg/kg adjuvant and 1.25 mg/kg p-AH1-A5 administered subcutaneously in 
mannose targeted LCP produced significant antigen-specific IFN-γ within the splenocytes pulsed 
with AH1 peptide. As shown in Figure 3-2A, all three vaccine formulations containing adjuvant 
significant increased IFN-γ production compared to mice vaccinated with a formulation void of 
any adjuvant or the PBS treated group. These results confirm that the adjuvants are necessary to 
induce a AH1 specific immune response. To confirm that these vaccines elicit a pro-inflammatory 
response and direct AH1 specific antigen cytotoxic T-lymphocyte killing, CTL analysis was 
performed. As shown in Figure 3-2B, the PBS and p-AH1-A5 vaccine formulations were not able 
to generate any detectable AH1 peptide–specific CTL response. However, mice that were 
immunized with the pAH1-A5 LCP containing the corresponding adjuvant provoked high AH1 
specific cytotoxic T-cell killing.  The data indicates that in all three formulations containing either 
CpG, cGAMP, or dsRNA that a robust adaptive immunity is elicited through the CD8+T-cytotoxic 
pathway. 
3.4.3 Modifying the immune cell populations in colorectal cancer (CRC) mice  
The colorectal cancer model was established through injection of 2 x 106 CT-26(FL3) cells 
into the mouse cecum wall and was first reported by Zhang et al. This model provides an aggressive 
colorectal liver metastasis platform in immune competent mice to investigate therapies ability to 
promote anti-cancer immune responses. The formation of large metastatic lesions and termination 
of the model due to large primary tumors in the intestine was reported 4 weeks post inoculation 44, 
and corresponded closely to the observed results. To more closely model clinical applications in 
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which a therapy is initiated following diagnosis of the tumor, the vaccine treatment was initiated 
six days post tumor inoculation with a vaccine boost administered six days post initial vaccination. 
Initial tumor studies were used to investigate and understand the different immune cell populations 
trafficking to the primary tumor following subcutaneous administration of the different adjuvant 
formulations. Therefore, on day 21 following tumor inoculation, mice were euthanized and the 
primary tumor, liver, and spleen were collected. The primary tumors were prepared for 
immunofluorescent microscopy and flow cytometry analysis. To investigate the morphology and 
collagen content of the tumors, the paraffin embedded tumor sections were Masson trichrome 
stained (Figure 3-3A). It is clear from the trichrome staining that the PBS, p-AH1-A5, and p-AH1-
A5 CpG tumors are high in collagen, which has been reported to promote tumor progression. 
Collagen deposition in the tumor microenvironment also has been directly implicated as a barrier 
to T-cell entry. Degradation of collagen in an ex vivo model resulted in markedly augmented 
penetration of T cells in the solid tumor microenvironment, enabling direct contact of T cells with 
tumor cells 73. To investigate the immune cell recruitment into the primary tumor following 
treatment, sections were stained for CD8+, CD4+, FOXP3+, CDllb+, and GR-1+ (Figure 3-3A). 
It is clear from the immunofluorescent microscopy analysis that the CD8 recruitment was 
significantly higher following vaccination of the p-AH1-A5 dsRNA LCP formulation compared 
to all other treatment groups. Furthermore, analysis of CD4+FOXP3+ (T-reg) cells and 
CD11b+GR-1+ (MDSCs) cells were significantly decreased in only the p-AH1-A5 dsRNA 
treatment group compared to the PBS group. Interestingly, all groups besides the pAH1-A5 
dsRNA group had minimal immune cell penetration into the tumor, in which most immune cells 
were located on the tumor periphery. This may be due to the increased MDSCs and T-reg 
localizing at the periphery and thwarting CD8+ tumor penetration. To confirm the 
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immunofluorescent results single tumor cell suspensions were stained for CD8+, CD4+, FOXP3+, 
CDllb+, and GR-1+, and analyzed via flow cytometry (Figure 3-3B, Figure 3-4). Similarly, as 
shown in Figure 3-3B, the percentages of T-reg and MDSCs were significantly reduced in the p-
AH1-A5 dsRNA treatment group compared to the PBS treated group, while the CD8+ population 
was significantly increased compared to the PBS group. The results indicated that although all 
three adjuvant formulations elicited robust IFN-γ production and AH1 antigen specific CTL killing, 
these results do not directly correlate with tumor recruitment and infiltration of CD8+ cells. This 
may be due to the higher number of immune suppressive cells being recruited to the tumor 
periphery. Furthermore, this may shed some insight into the different immune responses 
downstream following the activation of TLR9, STING, and RIG-1. 
3.4.4 Investigation of therapeutic efficacy in an orthotopic syngeneic colorectal liver 
metastasis model 
The effect of the immune response elicited by each individual vaccine and control on the 
primary colorectal tumor burden as well as on the incidence of liver metastasis found in mice was 
examined. Five treatment groups were explored, including PBS, p-AH1-A5 LCP containing no 
adjuvants, LCP containing p-AH1-A5 CpG, p-AH1-A5 cGAMP, and p-AH1-A5 dsRNA. 
Administration of treatment began six days following cancer cell implantation and a boost 
vaccination was administered six days following the first treatment. The treatments were 
administered subcutaneous in the left flank of the mouse (1.25 mg/kg p-AH1-A5/ 0.125 mg/kg 
adjuvant).  The total tumor burden was followed through intraperitoneal (IP) administration of 200 
µL of luciferin (10 mg/mL) followed by bioluminescent analysis 10 min post luciferin 
administration. The tumor burden was recorded every 2 to 3 days, and was used to sort mice into 
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treatment groups before treatment was initiated (Figure 3-5A). At the endpoint, 15 days post 
treatment initiation, mice were imaged and euthanized due to heavy primary tumor burden in the 
cecum. The livers were harvested and analyzed for metastatic lesions (Figure 3-5C). It is clear 
from the luciferase assay (bioluminescent intensity) that all mice developed large primary tumors 
by the study endpoint. However, the p-AH1-A5 dsRNA LCP treatment group showed reduced 
growth rates, in which the primary tumors burden was 3-6-fold lower than all other treatment and 
control groups (Figure 3-5A/B). Furthermore, analysis of the metastatic tumor lesions on the liver 
clearly indicate that the p-AH1-A5 cGAMP LCP and the p-AH1-A5 dsRNA LCP treatment 
significantly reduced tumor invasion and progression to the liver by 4-10-fold, respectively, 
compared to PBS control (Figure 3-5C). Analysis of liver sections further confirmed these results 
in which increased cirrhosis and fibrotic tissue is more prominent in the PBS, p-AH1-A5 LCP, and 
p-AH1-A5 CpG LCP treatment groups (Figure 3-5D).  This side by side comparison is possible 
due to the versatile LCP vector which is capable of efficiently encapsulating and delivering 
phosphorylated molecules.  
3.4.5 Effects of vaccine formulations on liver, kidney, and blood (toxicity analysis) 
Administration of vaccine formulations showed no significant changes in ALT, AST, 
creatinine, or BUN levels 14 days post vaccination (Figure 3-6). Further analysis of blood and 
immune cell levels showed no signs of change compared to control treated mice one and seven 
days post vaccination (Figure 3-6).  
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3.5 Discussions and Conclusion 
It has been well documented that the success of colorectal cancer vaccines correlates 
strongly with increased tumor infiltrating CD8+ T-cells 61 74. However, an increased number of 
tumor infiltrating CD8+ T-cells cannot promote an anti-cancer response in the presence of 
immune suppressive cells due to inactivation by T-reg and MDSCs in the tumor 
microenvironment 75-77. Therefore, in the study presented here, the goal aimed to investigate 
adjuvants which increased CD8+ T-cell populations, while not inciting an increase in immune 
suppressive cell populations. The three adjuvants used in this study were chosen due to their 
unique and distinct mechanism by which they elicit an immune response. The first adjuvant, 
CpG, binds to the nucleic acid sensors of the Toll-like receptor (TLR) family, in particularly 
TLR9. Binding to the TLR9 initiates signaling by aggregating the adaptor protein myeloid 
differentiation primary response protein 88 (MYD88). The MYD88 signaling cascade leads to 
the activation of nuclear factor-κB (NF-κB) and a pro-inflammatory cytokine response 78 79.  
The additional adjuvants formulated, 2’3’cGAMP and 5’pppdsRNA, bind to cytosolic nucleic 
acid sensors which are expressed in the cytosol of both immune and non-immune cells. The 
cyclic GMP–AMP, [G(2′,5′)pA(3′,5′)p] (2′3′cGAMP), functions as a messenger to activate the 
stimulator of IFN genes (STING) in the endoplasmic reticulum (ER) 68 78. The 5’pppdsRNA 
binds to the DExD/H-box helicases retinoic acid-inducible gene I (RIG-I; also known as 
DDX58). RIG-1 binds to short dsRNA structures and is activated by the 5′ triphosphorylated or 
5′ dephosphorylated end of the dsRNA 78. Complexation to RIG-1 in the cytosol produces 
inflammatory cytokines, chemokines and type I interferons 80. Although all three of these 
adjuvants have a well-defined and unique mechanism for eliciting a pro-inflammatory response, 
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the investigation of the pathophenotype is necessary to understand which adjuvants have the 
potential to translate from pre-clinical mouse models into human clinical studies. It has been 
shown that CpG-ODNs, achieve robust responses in mouse models, but have shown no 
promising efficacy in human anti-cancer studies. This is due to the varying TLR9 expression 
patterns between humans and preclinical test species, in which TLR9 has been found to be 
expressed in only a few human immune cell types. By contrast, RIG-I is broadly expressed in 
somatic and immune cells of both mice and humans and therefore may be a more promising 
target in terms of translatability. Interestingly, while all adjuvants elicited a robust IFN-γ 
response, it was found that the 5’pppdsRNA resulted in a significant increase in CD8 T-cells, 
while maintaining lower populations of T-reg and MDSCs within the tumor. This immune 
response resulted in a significant reduction in the tumor growth rate and development of liver 
metastasis compared to other treatment groups. 
However, to achieve full regression of the tumor, numerous manipulations in the tumor 
immune microenvironment must be established.  The vaccines investigated here are only one piece 
of achieving full regression of the tumor burden. Along with increasing the tumor infiltrating CTLs, 
it is necessary to also block the factors that play a fundamental role in cancer progression. The 
findings in Chapter 2 demonstrated that the targeting of immune modulating pathways can reduce 
cancer progression and the recruitment of immunosuppressive cell types to the tumor 
microenvironment 3. Therefore, future combination of these therapies with the model p-AH1-A5 
dsRNA LCP vaccine will allow for further investigation into which manipulations in the tumor 
immune microenvironment drives cancer regression in pre-clinical mouse models. 
In conclusion, all three adjuvant formulations incited similar pro-inflammatory responses 
measured by IFN-γ production and in vivo CTL. However, only the 5’pppdsRNA was able to 
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promote a significant anti-cancer response. This result is most likely due to maintaining low 
populations of immune suppressive T-reg and MDSCs present in the tumor microenvironment. 
Most importantly, this approach determined which adjuvant/vaccine formulation can achieve an 
enhanced antitumor response by increasing tumor infiltrating CD8 T-cells, while not inciting 
increased populations of immune suppressive cells. In Chapter 4, the use of this model 
adjuvant/vaccine formulation in combination with immune modulating therapies that are capable 
of further reducing the tumors ability to recruit immune suppressive cell types and promote tumor 
specific T-cell killing will be discussed. Investigating the synergistic anti-cancer responses of this 
model vaccine in combination with immune modulating therapies will aid in understanding the 
necessary immune manipulations needed to elicit robust and safe anti-cancer responses. Ultimately, 
this approach will guide the future investigation of more clinically relevant vaccines in 
combination with the most promising immune modulating therapies to elicit a robust anti-cancer 
response for the treatment of colorectal liver metastasis.  
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Figure 3-1 Characterization of formulated LCP nanoparticles containing phosphorylated adjuvant 
and antigen  
 
A) Graphical illustration of the LCP nanoparticle containing co-encapsulated 5’pppdsRNA and p-AH1-A5, 
the inner core consists of an amorphous calcium phosphate which aids in encapsulation of phosphorylated 
peptide and adjuvant, the inner lipid layer consists of DOPA, the outer lipid layer consists of cationic 
DOTAP, cholesterol helper lipid, DSPE-PEG, and DSPE-PEG-Mannose. B) The transmission electron 
microscopy (TEM) image and C) dynamic light scattering (DLS) zeta potential and size (number and 
volume average) of final LCP formulation with 5’pppdsRNA and p-AH1-A5. D) Biodistribution of 
mannose targeted LCP containing 5’pppdsRNA and 125I labelled p-AH1-A5 following subcutaneous 
injection at 4, 16, and 48 h. 
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Figure 3-2 In vivo immune response profile of LCP vaccines 
 
A) Interferon-γ (IFN-γ) production from the treated mice was measured through IFN-γ ELISPOT analysis. 
Spleens were collected from which single-cell suspensions were prepared 7 days after a single subcutaneous 
vaccination. The splenocytes were co-cultured with either β-gal or AH1 peptide at 37 °C for 18 h. The 
production of IFN-γ was calculated with a BD ELISPOT assay set. Two of the representative results are 
shown above. n = 6. B) In vivo CTL killing was measured through CFSE high/low staining of splenocytes 
collected from naive mice which were pulsed with either β-gal (low stain) or AH1 (high stain) peptide. The 
splenocytes were stained with 0.5 or 5 µM carboxyfluorescein succinimidyl ester (CFSE), respectively. The 
mix of both pulsed cells at a ratio of 1:1 were injected into the vaccinated mice via tail vein. 16 h after 
injection, mice were euthanized and splenocytes were collected, washed, and analyzed via flow cytometry. 
The specific lysis activity of CTL was calculated using the equation mentioned in the Materials and 
Methods section. n = 6. A representative graph from each treatment is shown. Data was expressed as mean 
± s.d. N.S. denotes no significance, N.D. denotes under detection limit, *, **, or *** denotes p < 0.05, 0.01, 
or 0.001, respectively.   
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Figure 3-3 Immune cell (MDSC, T-reg, CD4+ and CD8+ T-cell) recruitment within primary 
colorectal cancer tumors 
 
A) Changes of tumor-infiltrating immune cells in tumor microenvironment. The CT-26FL3 colorectal 
cancer mice were divided into five treatment groups, including PBS control, p-AH1-A5 LCP, p-AH1-A5 
CpG LCP, p-AH1-A5 cGAMP LCP, and p-AH1-A5 dsRNA vaccines. On day 21, mice were euthanized 
and tumor tissues were collected for A) Immunofluorescence microscopy and B) Flow cytometry analysis. 
The statistical analyses were calculated by comparison with the control group if not specifically mentioned. 
Data was expressed as mean ± s.d., calculated from samples ran in triplicate. N.S. denotes no significance, 
N.D. denotes under detection limit, *, **, ***, **** denotes p < 0.05, 0.01, 0.001, or 0.0001, respectively, 
compared to corresponding PBS control. Scale bar: 200 μm. 
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Figure 3-4 Flow cytometry analysis of immune cell populations (CD8, CD4, T-reg, and MDSCs) 
within primary tumor and spleen  
 
A) CD8, B) CD4, C) MDSC (CDllb+GR-1+), D) T-reg (CD4+FOXP3+) immune cell population in tumor. 
E) CD8, F) CD4, G) MDSC (CDllb+GR-1+), H) T-reg (CD4+FOXP3+) immune cell population in spleen. 
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Figure 3-5 Reduced tumor growth and liver metastasis following p-AH1-A5 dsRNA LCP treatment 
  
 A) Inoculation and treatment schedule/dose, tumor mass on days 3, 9 and 15 post first treatment 
administration. Mice were inoculated with 2x106 CT-26(FL3) RFP/Luc cells into the cecum wall. 
Treatment of 1.25 mg/kg p-AH1-A5 and 0.125 mg/kg adjuvant on days 0 and 6 was administered through 
subcutaneous injection. Treatment groups included PBS (n=10), p-AH1-A5 LCP (n=7), p-AH1-A5 CpG 
LCP (n=6), p-AH1-A5 cGAMP LCP (n=6), and p-AH1-A5 dsRNA LCP (n=7). Progression of overall 
tumor mass was followed by administration of 200 µl luciferin (10mg/mL) IP. Luciferase bioluminescent 
imaging was recorded 10 min after administration of luciferin.   B) Quantification of tumor burden was 
quantified using image IVIS/Kodak software and recorded as fold change over day 0 tumor burden. C) 
Liver metastasis tumor burden was quantified through visual analysis of the livers on day 15, endpoint. 
Number of metastatic lesions were counted and recorded. Data was expressed as mean ± s.d., calculated 
from samples. N.S. denotes no significance, N.D. denotes under detection limit, *, **, or *** denotes p < 
0.05, 0.01, or 0.001, respectively, compared to corresponding PBS control. 
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Figure 3-6 Toxicological analysis 
 
A) ALT, AST, creatinine, and BUN enzyme levels, blood cell levels, after treatment of PBS, p-β-gal LCP, 
p-AH1-A5 LCP, p-AH1-A5 CpG LCP, p-AH1-A5 cGAMP LCP, p-AH1-A5 dsRNA LCP, treatment dose 
was 1.25 mg/kg p-AH1-A5, and 0.125 mg/kg adjuvant, administered subcutaneously on days 0 and 6. 
Mouse blood was collected via tail vein nick on days 1 and 7 following treatment and analyzed for blood 
cell levels. Mice were sacrificed 14 days post final injection and blood serum was collected and analyzed 
for liver and kidney biomarkers. All LCP treatments fall within normal range. Data was expressed as mean 
± s.d., calculated from samples ran in triplicate, *, **, or *** denotes p < 0.05, 0.01, or 0.001, respectively, 
compared to corresponding untreated control. 
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4. Chapter 4 Resolving the Immune Suppressive Microenvironment and 
Enhancing the Anti-Cancer Immune Response via a Combination of 
Gene-Immunotherapies (pCXCL12/pPD-L1 traps) and a Robust 
Adjuvant/Peptide Vaccine for the Treatment of Liver Metastasis4 
4.1 Overview 
Immunotherapies such as anti-PD-L1 and anti-CXCL12 are promising and potent anti-
cancer treatments. However, the systemic delivery of these antibodies has barriers which reduce 
efficacy and increase off-target toxicities. Here, an alternative approach for the delivery of 
immunotherapies, in which the delivery of pDNA of an engineered PD-L1 and/or CXCL12 trap 
to the nucleus of liver hepatocytes via a lipid calcium phosphate nanoparticle was explored. This 
strategy could increase immunotherapy concentrations in the local tissue, allowing the therapy to 
simultaneously inhibit the accumulation of immune suppressive cells and liver metastasis. 
The lipid calcium phosphate nanoparticles containing the pPD-L1 and pCXCL12 trap reduced 
the liver metastasis burden in an aggressive colorectal liver metastasis model (10 fold), 
ultimately prolonging the survival time in mice (>70%).  Furthermore, this combination therapy 
resolved the formation of immune suppressive ectopic lymphoid structures commonly associated 
with liver metastasis. The reduced immune suppressive microenvironment allowed for increased 
                                                   
4 This chapter previously appeared as an original research article. The original citation is as follows: 
Goodwin T. S, L., Hu, M., Li, J., Feng, R., Liu, R., Huang, L. Liver Specific Gene Immunotherapies 
Resolve Immune Suppressive Ectopic Lymphoid Structures in Microniche of Liver Metastases and 
Prolong Survival. 2017; Publication Pending 
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T-cell activation and migration into the liver following vaccination against tumor antigens 
(>180% increase in survival).  Interestingly, the pPD-L1 and pCXCL12 trap showed superior 
efficacy in the treatment of the liver metastasis compared to free protein immunotherapies. It is 
hypothesized that this alternative strategy of delivering genes encoding potent immunotherapies 
for increased local concentrations in the liver reduces off-target concentrations, while increasing 
therapeutic efficacy. This strategy reduces the progression of liver metastasis as well as the 
formation of immune suppressive ectopic lymphoid structures, and should be considered as an 
alternative approach to supplement and support current liver metastasis therapies as well as for 
future research interested in manipulating the chemokine/cytokine immune factors within the 
liver.  
4.2 Introduction  
In the United States alone approximately 381,150 patients were diagnosed with colorectal 
cancer, resulting in over 89,640 deaths in 2015. These numbers make colorectal cancer the third 
most common type of cancer in worldwide, and is the second most deadly 60.The cause of death is 
rarely due to the primary cancer burden, as local resection is quite efficient. The establishment of 
metastasis is the leading cause of death, in which at early stages of cancer detection, before 
metastases form, the five-year survival rate is approximately 90%. Once liver metastasis has 
established, this rate drops drastically to less than 12% 60. Upon diagnosis 20% of patients have 
developed metastasis, and 60-70% of patients develop metastatic lesions by time of death. In the 
United States and Europe, liver metastasis is much more common than primary liver cancers such 
as hepatocellular carcinoma (HCC). Although resection and varying chemotherapeutic treatment 
regimens are currently the standard of care and yield improved efficacy over other traditional 
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treatments, the off-target toxicities along with a minimal increase in median survival, 12-20 
months, presents a less than desirable outcome 34. Therefore, many are looking to improve the 
treatment of cancers through boosting the patient’s own immune system against cancer specific 
antigens. Numerous anti-cancer vaccines for colorectal liver metastasis are being investigated in 
clinical trials. However, no anti-cancer vaccine for colorectal liver metastasis has reached the 
market due to lack of efficacy or systemic toxicities. The liver and tumors immune suppressive 
microenvironment is one major obstacle which must be overcome before these vaccines will have 
a significant impact on cancer patients. Recently, a study by Finkin et al. reported that the 
formation of immune suppressive ectopic lymphoid structures (ELS) in patients correlated with 
reduced survival and increased recurrence of liver cancer 81. Therefore, targeting central factors 
that are critical to the formation and establishment of the immune suppressive tumor 
microenvironment and ELS is one such strategy to decrease tumor burden.  
A central factor, CXCL12, has been shown to increase tumor progression through promoting 
the immune suppressive environment that suppresses CD8+ T-cell activation. The hepatic stellate 
cells are resident perisinusoidal cells that have been shown to produce high levels of endogenous 
CXCL12 for recruitment of immunosuppressive lymphocytes (i.e. regulatory T cells) and myeloid 
derived suppressor cells (MDSCs) to areas of inflammation. In the presence of high levels of 
CXCL12, CXCR4+ cancer and immune cells accumulate to establish an immune suppressive 
tumor niche40 41. Further clinical analysis on human colorectal cancer biopsies have found that 
increased liver metastasis correlates with increasing CXCR4 expression 39 42.   
Additionally, major progress has been made in recent years aimed at increasing CD8+ T-
cell activation through blocking the programmed cell death 1/programmed cell death 1 ligand 1 
(PD-1/PD-L1) receptor/ligand pair. It has been well documented that the immune suppressive cell 
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populations such as T-regulatory (T-reg), MDSCs, and numerous other immune cell types express 
high levels of PD-L1 which directly deactivates PD-1+ T-cells.  Therefore, this PD-L1/PD-1 has 
become a promising target to increase tumor specific CD8+ T-cell activation and killing. However, 
while PD-1/PD-L1 targeting in cancer has shown beneficial responses in some cancer types such 
as melanoma, it has not shown great potency in immune suppressive cancers such as liver 
metastasis. Furthermore, a variety of side effects termed immune-related adverse events (irAEs) 
have been observed following systemic delivery of PD-1/PD-L1 antibodies, which has limited 
their therapeutic applications in the clinical trials 29. 
Therefore, a new anti-cancer strategy centered on the liver-specific delivery of genes 
encoding small antibody-like proteins to entrap such factors as CXCL12 and/or PD-L1 was 
developed. This strategy aims to alter the liver microenvironment and ultimately halt metastasis to 
the liver.  In Chapter 2, this strategy of disrupting the CXCL12 in the liver was demonstrated. This 
approach effectively decreased the occurrence and progression of colorectal and numerous other 
CXCR4+ cancers from developing in the liver, while drastically reducing the recruitment of 
immunosuppressive cells. However, through these studies it was found that trapping CXCL12 can 
only decrease the incidence of liver metastasis for a limited time due to low CD8+ T-cell 
recruitment and activation in the metastatic niche. Therefore, it is hypothesized that it is necessary 
to utilize a combination of therapies aimed at reducing the immune suppressive environment while 
simultaneously increasing CD8+ T-cell recruitment and activation.  
Therefore, in the current study, the LCP platform was utilized to deliver two engineered 
plasmid DNAs (pCXCL12 trap/pPD-L1 trap) encoding proteins targeting CXCL12 and PD-L1 to 
treat colorectal liver metastasis. The small CXCL12 protein trap, CXCL12 trap, was designed 
based on an anti-CXCL12 antibody sequences, by fusing a VH and a VL domain. The CXCL12 
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trap is ~28.6 kDa, and found to have a strong binding affinity (~4.1 nM Kd) to CXCL12 3. The 
PD-L1 protein trap, PD-L1 trap, was developed based on the ability to convert the extracellular 
PD-1 binding domain from endogenous PD-1 into a trivalent ligand through incorporation of a 
trimerization domain. The resulting trivalent PD-L1 trap protein is ~136 kDa with approximately 
219 pM binding affinity to mouse PD-L1. This approach generated a trap with more than 82,000 
times higher affinity compared to endogenous PD-1 and PD-L1 (Miao et al., publication pending). 
Furthermore, to increase the CD8+ T-cell activation and recruitment to the metastatic niche, a 
previously reported LCP vaccine formulation loaded with a RIG-1 ligand, 5’pppdsRNA, and a 
phosphorylated model cancer specific antigen, p-AH1-A5 was used (Chapter 3).     
The establishment of an aggressive murine colorectal liver metastasis via hemi-splenic 
inoculation of CT-26FL3 (RFP/Luc) allows the investigation of the therapies ability to alter the liver 
microenvironment and the tumor/immune cell profile. Furthermore, this model has minimal primary 
tumor growth, due to surgical resection, which mirrors the clinical scenario of colorectal liver 
metastasis patients in which the primary tumors are resected. The use of this syngeneic model also 
mirrors the clinical cases of the liver metastasis immune environment in which numerous immune cell 
ELS aggregates are established. Therefore, investigating strategies to resolve the establishment of these 
aggregates as well as promoting CD8+ T-cell recruitment to the metastatic niche will be further 
elucidated.  
4.3 Material and Methods 
4.3.1 Materials 
1,2-Distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[succinyl(polyethylene glycol)-
2000]-N-hydroxysuccinimide (DSPE-PEG2000–N-hydroxysuccinimide (NHS)) was purchased 
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from NOF Corporation (Tokyo, Japan). DSPE-PEG2000-galactose and DSPE-PEG2000-mannose 
was synthesized through the conjugation of 10 eq. of 4-aminophenyl β-d-galactopyranoside or 
mannose and 1 eq. of DSPE-PEG2000-NHS in PBS buffer, followed by chloroform extraction and 
dialysis against water using a MWCO 1000 dialysis tube. All other lipids were purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL). Peptide (mcCR8C) was purchased from Elim 
Biopharmaceuticals, Inc. (Hayward, CA); monocyclic abbreviated to mc. Peptides (AH1, p-AH1-
A5, and β-gal) were purchased from Peptide 2.0 (Chantilly, VA). Fluorescent Cy3 cDNA labelling 
kit was acquired via Mirus LabelIT kit (Mirus Bio, Madison, WI). Luciferin was purchased from 
Promega Corporation (Madison, WI). Plasmids encoding green fluorescent protein (GFP) driven 
by the cytomegalovirus (CMV) promoter were custom prepared by Bayou Biolabs (Harahan, LA). 
IF and IHC kits as well as all antibodies were purchases through Abcam (Cambridge, MA). All 
other chemicals were obtained from Sigma-Aldrich (St. Louis, MO) and used without further 
purification. Anti-His(6x) tag ELISA, Anti-Lyt2.2 and isotype controls were purchased from 
BioXcell (West Lebanon, NH). Six-week-old BALB/c female mice (∼18 g each) were purchased 
from Charles River Laboratories (Wilmington, MA). Six-week-old nude female mice (∼20 g each) 
were purchased from the University of North Carolina (Chapel Hill, NC).  All work performed on 
animals was in accordance with and approved by the University of North Carolina Institutional 
Animal Care and Use Committee. 
4.3.2 Study design 
This was a preclinical study to assess the efficacy, safety, and biological effects of two 
promising engineered gene immunotherapies (pCXCL12 trap and pPDL1 trap) as well as the effect 
in combination with a potent vaccine (p-AH1-A5 5’pppdsRNA) delivered via a non-viral vector. 
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In Chapter 2, it was shown that neutralization of the high levels of endogenous CXCL12 produced 
by the hepatic stellate cells in the inflamed liver decreased the migration, invasion, and 
proliferation of colorectal liver metastasis as well as shifted the immune environment from anti- 
to pro-inflammatory. However, the therapeutic efficacy was thwarted in more aggressive liver 
metastasis models in which increased formation of immune suppressive ectopic lymphoid 
structures (ELS) deactivated the tumor specific CD8 T-cells. Therefore, the hypothesis aims to 
understand how to resolve the immune suppressive ELS while increasing the activation of cancer 
specific CD8 T-cells to induce an improved anti-cancer response. This hypothesis was tested 
through an established syngeneic colorectal liver metastasis murine model in which two additional 
CD8 promoting therapies (pPDL1 Trap LCP and p-AH1-A5+5’pppdsRNA LCP) were delivered 
alongside the pCXCL12 Trap LCP. The number of mice used for the in vivo experiments are 
outlined in the figure legends. Grouping for tumor experiments was done through measuring the 
tumor burden via bioluminescent techniques, ranking, and distributing equally among groups or 
through randomized blind selection in cases where treatment was initiated on day 0. Additional 
study design details are also included in the statistical analysis section.   
4.3.3 CT-26(FL3) (RFP/Luc) culture 
CT-26(FL3) cells were obtained from Dr. Maria Pena’s lab at the University of South 
Carolina, and cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM) with 4.5 g/L 
glucose (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% 
Penicillin/Streptomycin (Pen/Strep, Gibco) at 37°C and 5% CO2 in a humidified atmosphere. 
Lentivirus transfection of cell line was performed in which CT-26(FL3) cells were incubated in 
media containing lentivirus.  Cells stably transfected with the vector carrying the mCherry red 
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fluorescent protein (RFP), firefly luciferase (Luc), and the puromycin resistance gene were 
analyzed under fluorescent microscope. Stably transfected CT-26(FL3) cells were selected in the 
presence of puromycin.  
4.3.4 Preparation of LCP loaded with pDNA  
LCP was prepared using a modified protocol 9,10. Two separate microemulsions (60 mL 
each) were prepared of Igepal 520 and cyclohexane (3:7 v/v) and placed under stirring. A pDNA 
(800 μg) solution was prepared and added to 1,800 μL of 2.5 M CaCl2. To this solution, 
octaarginine peptide (mc-CR8C) was added at an N:P ratio of 2:1 (~850 µg), this solution was 
immediately added to the microemulsion before precipitation could occur. A (NH4)2HPO4 solution 
(1,800 μL, 50 mM) was also prepared and added to the other microemulsion. Each microemulsion 
was stir for 20 min. The microemulsion containing (NH4)2HPO4 was added to the microemulsion 
containing the DNA/Peptide/CaCl2. This solution was stirred for 5 min before addition of 1,400 
μL of 20 mM DOPA (in CHCl3). After addition of DOPA the microemulsion was stirred for an 
additional 30 min. An equal volume of 100% EtOH (120 ml) was added to disrupt the emulsion. 
The mixture was centrifuged at 10,000g for 20 min. After decanting the supernatant, the precipitate 
was washed, including vortex and sonication, twice thereafter with 100% EtOH to remove traces 
of Igepal and/or cyclohexane. The precipitate was then suspended in CHCl3. This solution was 
centrifuged at 14,000 rpm for 10 min for the removal of large aggregates, and the supernatant 
containing the LCP “cores” (DNA and peptide entrapped within a calcium phosphate 
nanoprecipitate, supporting and surrounded by a lipid monolayer of DOPA) was recovered. A 
single batch typically produces approximately 45 mg of cores, encapsulating approximately 450 
µg pDNA. The ratio of cores to outer leaflet lipids for optimal final particle formulation was found 
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to be 3.0 mg core:  225 µl DOTAP (20 mM): 225 µl Cholesterol (20 mM): 200 µl DSPE-PEG2000 
(20 mM). Therein, 35 mol % DOTAP, 35 mol % cholesterol, and 30 mol % DSPE-PEG2000 (or 
25 mol % DSPE-PEG and 5 mol % DSPE-PEG-Gal) were utilized as outer leaflet lipids. Addition 
of 0.1% (w/w) Tween 80 was added to the chloroform solution containing the cores and outer 
leaflet lipids. Preparation of final particles for injection followed formation of lipid film through 
drying off chloroform with nitrogen gas, followed by resuspension in 10% aqueous sucrose 
solution and sonication. Zeta potential and particle size of LCP were measured using a Malvern 
ZetaSizer Nano Series (Westborough, MA). TEM images of LCP were acquired using a JEOL 
100CX II TEM (JEOL, Japan). 
4.3.5 Characterization of LCP loaded with pDNA  
DNA entrapment was characterized through several methods. Firstly, pDNA was labeled 
with Cy3 (Mirus LabelIT kit, Mirus Bio, Madison, WI) per manufacturer instructions. Cy3-DNA 
was formulated into the LCP cores, after which recovery was assessed via fluorescence 
spectrometry. Additional encapsulation studies followed tritium labelling of the pDNA. The 
pDNA was dissolved in 100 uL of tritium water (5 uCi) and heated to 80 degrees Celsius for 6 h. 
pDNA was purified through sequential washing with cold DI water and filtration via 3000 MWCO 
centrifuge filter tubes. Standard curves were generated using a scintillation counter, along with 
known concentrations of peptide/pDNA complexes and used to calculate pDNA encapsulation 
efficiency (50-60%).  
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4.3.6 In vivo gene biodistribution and expression time profile  
Formulation of galactose targeted LCPs containing pCXCL12 or pPDL1 Trap DNA, which 
contains a His(6x)-Tag at the C-terminal end were injected (0.2 mL, balanced in osmolarity with 
the addition of sucrose) into 8-week-old BALB/c female mice (1 mg DNA/kg, 3 mice utilized for 
each group) through the tail vein. Mice were euthanized 1, 2, 4, and 8 days after administration. 
Liver, spleen, lungs, kidney, heart, and blood were collected and homogenized in RIPA buffer. 
Total protein concentration in the lysate was determined through a bicinchoninic acid protein assay 
kit (BCA Protein Assay Kit, Pierce, Rockford, IL). Subsequently, His-tag ELISA kit was also used 
in which samples were loaded for expression analysis. The kit provided standard proteins 
containing a His (6×)-tag to be used as a standard calibration control. Therefore, quantification of 
protein expression can be measured through ELISA analysis following BioXcell protocol. The 
CXCL12 and PDL1 trap proteins were also injected and analyzed to compare with the pDNA LCP 
expression profile. 
4.3.7 Toxicity and pathology studies  
Mice were treated (1.0 mg DNA/kg x 3, QOD) (three mice utilized for each group) and 
analyzed for toxicity 1, 7, and 14 days post final injection. Furthermore, corresponding control 
protein treatment groups (1.0 mg protein/kg x 3, QOD) were analyzed for toxicity markers on days 
1, 7, and 14 post final injections. Serum was obtained from the mice via cardiac puncture and 
centrifugation. Hepatic and renal damage was assessed by measuring the levels of AST, ALT, 
creatinine and BUN in the serum samples on day 14. Blood cell levels, including white blood cells, 
lymphocytes, granulocytes, and monocytes were measured with whole blood analysis on days 1 
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and 7. These measurements were quantified by the Animal Clinical Chemistry and Gene 
Expression Laboratories at UNC Chapel Hill. 
4.3.8 Orthotopic allografting in mice 
Sub-confluent cells were harvested and washed in phosphate buffered saline (PBS) just 
prior to spleen implantation. Eight-week-old male BALB/c mice were anesthetized by inhalation 
of isoflurane (2%) via a vaporizer and placed in supine position. For splenic inoculation, an 
incision located below the left rib cage was made to exteriorize the spleen. The spleen was tied 
and cut into two parts each containing intact vascular pedicle for each half of the spleen. The distal 
section of the spleen was inoculated with 1x105 CT-26 (RFP/Luc) cells in 100 µL. The hemi-
spleen containing inoculated cells was resected 5 mins after inoculation allowing the cancer cells 
to enter the portal vein. The hemi-half containing inoculated cells was resected to model primary 
tumor resection. The other half of the spleen was returned to the cavity and the abdominal wall 
and skin were closed with 4-0 polyglycolic acid sutures.  
4.3.9 Luciferase imaging of whole animal and ex vivo tissues 
Luciferase imaging of tissue and animals was performed as follows in which D-luciferin 
of 1.0 mg/ 10g body weight was injected intra-peritoneally into mice. Following 10 min post 
administration, luciferase imaging (IVIS-Kinetic) was applied on whole-mouse bodies. For ex vivo 
imaging, mice were dissected 10 min after luciferin injection. Livers were rinsed in PBS and placed 
in diluted luciferin solution (2 mg/ml) for 1 min. Organs were then placed in IVIS in which 
luciferase imaging was applied immediately. Imaging and quantification were performed at the 
UNC Biomedical Research Imaging Center (BRIC) using the IVIS kinetic optical imaging system. 
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Quantification of bioluminescent signal was reported as either the raw average intensity, tumor 
volume fold change, or normalized.  
4.3.10 Immunohistochemistry 
Histology and immunohistochemistry were performed on paraffin-embedded or frozen 
sections from major organs and organs containing metastatic lesions. All paraffin-embedded tissue 
was resected, rinsed in PBS, and placed in 4% paraformaldehyde for 48 h at 4°C. Following 4% 
PFA, tissues were rinsed in water and placed in 70% ethanol solution until paraffin-embedded. All 
tissues for frozen sections were resected and rinsed in PBS, and placed in 2% paraformaldehyde 
overnight at 4◦C. Following 2% PFA, tissues were placed in 30% sucrose/PBS solution overnight 
at 4°C. Tissues were snap frozen in O.C.T. (Fisher Scientific, Pittsburgh, PA). 
Immunofluorescence staining was processed through deparaffination, antigen retrieval, 
permeabilization, and blocking in 1% bovine serum albumin at room temperature for 1 hour. 
Primary antibodies conjugated with fluorophores (BD) were incubated overnight at 4°C and the 
nuclei were counterstained with 4',6-diamidino-2-phenylindole containing mounting medium 
(Vector Laboratories, Burlingame, CA). All antibodies were diluted after optimization. Images 
were taken using fluorescence microscopy (Nikon, Tokyo, Japan). A minimum of three randomly 
selected microscopic fields were quantitatively analyzed using Image J software. 
4.3.11 Flow cytometry 
Liver/Metastasis cells and splenocytes were made into single-cell suspensions. Immune 
lymphocytes were quantitatively analyzed by flow cytometry via immunofluorescent staining. 
Tissues were harvested and digested with collagenase A and DNase at 37 °C for 45 min. After red 
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blood cell lysis via addition of ACK buffer, cells centrifuged at 2,000 g for 10 min. Following 
centrifugation, samples were washed and resuspended in 1 mL of phosphate-buffered saline. Cells 
were counted and diluted to 5×106 cells/mL. Cells were then stained by addition of the fluorescent-
conjugated antibodies. For intracellular FOXP3 staining, the cells were permeated via penetration 
buffer (BD, Franklin Lakes, NJ) following the manufacturer's instructions. Following staining cells 
were fixed and analyzed via FACS.   
4.4 Results  
4.4.1 Formulation and characterization of galactose-LCP pDNA-mc-CR8C nanoparticles  
Hu et al. first reported the formulation and delivery of the galactose-LCP with pDNA-mc-
CR8C cargo to the liver hepatocytes of mice 2. The formulation of the pCXCL12 trap LCP was 
reported by Goodwin et al. and the methods used in the cited paper will be used for all pTrap LCP 
formulations used in this study 3.  Furthermore, the 5’pppdsRNA p-AH1-A5 LCP vaccine 
formulation was first reported by Goodwin et al. (publication pending) which is based on the 
phosphorylated peptide LCP vaccine formulation first reported by Xu et al 72. The core structure 
can be visualized under transmission electron microscopy (TEM) (Figure 4-1B). The DOPA 
monolayer surrounding the CaP core allows for the addition of the cationic outer leaflet lipids (1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP), helper lipid cholesterol, and galactose or 
mannose conjugated to 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-
[succinyl(polyethylene glycol)-2000 (DSPE-PEG2000) to assist in RES evasion and dendritic cell 
(mannose) or hepatocyte (galactose) uptake. In this report the hydrodynamic diameter and the 
surface charge of the LCP particles were found via dynamic light scattering zetasizer analysis to 
be approximately 45 nm and 10 mV, respectively (Figure 4-1B). The pDNA encapsulation 
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efficiency was found to be approximately 50-60%. The p-AH1-A5 and 5’pppdsRNA 
encapsulation efficiency was found to be approximately 70%, which corresponds to the reported 
efficiency by Goodwin et al. (publication pending).  
4.4.2 In vivo expression profile of pDNA (pPD-L1 and pCXCL12 trap) via LCP formulation 
Expression of the pCXCL12 trap and pPD-L1 was assessed through ELISA analysis via 
the His(6×)-tag engineered at the C-terminus of the protein traps (Figure 4-1A). Mice were treated 
via IV injection of pCXCL12 or pPD-L1 trap LCPs and compared to the free CXCL12 or PD-L1 
protein traps (1 mg/kg QOD x 3). Studies demonstrated the transient expression time profile 
following analysis of the livers, serum, spleen, and kidneys on days 1, 2, 4, and 8 following final 
IV administration is shown in Figure 4-1C. The results indicate that the pDNA LCP vectors elicits 
transient liver specific expression of the CXCL12 or PD-L1 trap, yielding high expression for 4 
days post final injection with minimal trap expression found on day 8 (Figure 4-1C). These results 
demonstrate that the galactose-LCP vector allows for local and transient expression in the liver 
hepatocytes, with minimal expression in other organs or serum compared to the IV administration 
of free CXCL12 or PD-L1 traps (Figure 4-1C). 
4.4.3 Therapeutic efficacy and increased survival via pCOMBO traps LCP treatment 
Colorectal liver metastasis was established through a hemi-spleen model to mirror clinical 
cases in which the primary tumor in colorectal liver metastasis patients is resected. The formation 
of large metastatic lesions and termination of the model due to the aggressive growth of metastasis 
in the liver is approximately 14 days post inoculation. Investigation of the tumor burden and 
survival of mice with colorectal liver metastasis was followed by IVIS bioluminescence imaging. 
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The total tumor burden was followed through intraperitoneal (IP) administration of 200 µL of 
luciferin (10 mg/mL) followed by bioluminescence analysis 10 min post luciferin administration. 
The tumor burden was recorded on days 4, 6, 9, and 12 and quantified as tumor volume change 
(Figure 4-2A). Mice were sorted into treatment groups on day 4 when liver metastasis burden is 
present. Mice were euthanized due to heavy liver tumor burden in which mice became lethargic or 
showed signs of ascites and survival was recorded (Figure 4-2B). It is clear from the 
bioluminescence images that mice treated with PBS, pGFP LCP, or free combo protein traps 
developed large metastatic tumor lesions in the liver (Figure 4-2A). In contrast, mice treated with 
pCXCL12 trap LCP, pPD-L1 trap LCP, or pCOMBO traps LCP resulted a significant (~2-6 fold) 
reduction in liver metastasis burden. Interestingly, although the pCXCL12 and pPD-L1 trap LCP 
groups had a greater than 2-fold reduction in liver tumor burden on day 12, the median survival (7 
days after final treatment was administered) was the same as the controls due to ascites. The 
pCOMBO trap LCP treatment significantly extended the median survival by 70% (12 days after 
treatment).  
4.4.4 Decreasing the immune suppressive cell populations and metastasis in liver of 
colorectal cancer (CRC) 
Further investigation into the changes in the immune cell populations within the liver 
metastasis and the therapeutic efficacy of this strategy was observed via flow cytometry and 
bioluminescence analysis. Mice bearing colorectal liver metastasis were treated with either single 
arm treatments including pCXCL12 trap LCP or pPD-L1 trap LCP, or combination treatments 
including the combo protein traps, or pCOMBO traps LCP. The controls included a PBS and pGFP 
LCP treatment. Treatment regimen and doses are shown in Figure 4-3A. The livers were extracted 
12 days following splenic inoculation of the tumor cells and were analyzed for metastatic lesions 
 101 
 
via IVIS bioluminescence imaging. The bioluminescence data clearly shows the reduced 
metastatic burden following single arm treatments with pCXCL12 or pPD-L1 trap LCP and a 
synergistic effect following pCOMBO traps LCP treatment. Flow cytometry analysis further 
agrees with the previous microscopy data in which the immune suppressive cell types are reduced 
following pCOMBO traps LCP treatment (Figure 4-3B and Figure 4-4). Interestingly, the pPD-
L1 trap LCP alone shows no significant decrease in the PD-L1+ cell within the liver. However, 
the pCXCL12 trap and the combined therapy, which significantly reduces the recruitment and 
establishment of the immune suppressive cells, drastically reduces the PD-L1+ cells recruited to 
the liver lesions. Interestingly, the pCOMBO trap not only decreased the immune suppressive cell 
populations, but significantly increased the M1/M2 macrophage ratio, and the natural killer (NK) 
cell populations found within the liver (Figure 4-3B, Figure 4-4). The decreased immune 
suppressive cells along with the increases in M1/M2 and NK indicates a shift from a pro-tumor 
(immune suppressive) to anti-tumor environment within the liver. However, the minimal increase 
in the CD8+ T-cells indicates that the adaptive immune system needs a more robust signal to 
increase activation and invasion towards the metastatic niche. 
4.4.5 Modifying the immune cell populations in liver of colorectal liver metastasis model 
The changes in the immune cell profile within the liver metastasis was investigated 
following treatment with the pCXCL12 trap, pPD-L1 trap, and the pCOMBO traps through 
microscopy analysis. Adjacent paraffin embedded liver sections were stained with Masson 
trichrome or immunofluorescent tagged antibodies (Figure 4-5A/B). It is clear from the results 
that the pCOMBO traps LCP treatment significantly reduces the establishment of immune cell 
aggregates, ELS, in the livers of CRC mice to a level observed in a healthy liver control (Figure 
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4-5A). The expression levels of endogenous CXCL12 and PD-L1, along with the establishment of 
ELS in the liver of colorectal cancer bearing BALB/c mice were also investigated in all treatment 
groups (Figure 4-5B). Interestingly, similar to the flow cytometry analysis, the pPD-L1 trap shows 
minimal decrease in the PD-L1 expression within the liver. It is hypothesized that this is due to the 
majority of PD-L1+ cells within the liver residing in the ELS. Therefore, the pPD-L1 trap is unable 
to extravagate to the center of the established ELS, in which the ELS acts as a binding site barrier. 
However, the pCXCL12 trap and pCOMBO traps, which significantly reduces the recruitment and 
establishment of the ELS, also reduces the PD-L1+ cells recruited to the liver lesions. In comparing 
the PBS or free combo protein traps to the pCOMBO trap LCP groups, the pCOMBO traps therapy 
greatly resolves the establishment of ELS and metastatic lesions. The mice treated with PBS 
develop numerous metastatic lesions, with the majority forming near liver blood vessels and 
sinusoids. Interestingly, most of these metastatic lesions display a high number of large immune 
cell ELS aggregates proximal to the blood vessels and sinusoids (Figure 4-5A). The results 
indicate that there is a drastic decrease of all immune cells following pCOMBO traps LCP 
treatment. Staining of MDSCs, T-reg, B-reg, CD8+, and NK+ cell populations show increased 
populations aggregated in the PBS treated mice compared to the healthy (no liver mets) and 
pCOMBO traps LCP groups. The pCOMBO traps LCP group showed baseline levels of immune 
cell aggregates similar to the healthy liver. However, a small increase was observed in the CD8+ 
T-cell population in the pCOMBO traps LCP group compared to the healthy group (Figure 4-5A). 
This seems to provide insight into the metastatic lesions’ ability to cause local inflammation, which 
results in increased levels of CXCL12, collagen, and subsequently an influx of PD-L1+ anti- and 
pro-inflammatory immune cells which aggregated to form ectopic lymphoid structures 
surrounding the metastatic lesions (Figure 4-5A/B). Although the PBS group have the highest 
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influx of CD8+ T-cells, the high level of immunosuppressive MDSCs and T-reg populations is 
likely to neutralize the NK and CD8+ T-cells mediated cancer specific killing. 
4.4.6 Priming the metastatic liver microenvironment and the immune system increased 
survival 
The ability to control the local immune suppressive microenvironment of metastatic lesions 
following pCOMBO traps LCP treatment allows for the investigation into potential synergy when 
combined with cancer specific vaccines. Therefore, the therapeutic efficacy of a combination 
treatment regimen consisting of a robust cancer vaccine, p-AH1-A5+5’pppdsRNA LCP, and the 
pCOMBO traps LCP (pCOMBO p-AH1-A5 LCP) was examined. Furthermore, to investigate 
what subtype of T-cells are responsible for tumor specific killing, the anti-cancer efficacy of the 
combination treatment in mice with a depleted CD8+ or CD4+ T-cell populations was studied. A 
protocol reported by Harimoto et al., in which ≥95% of the CD8+ or CD4+ T-cell populations 
were depleted after two intraperitoneal injections of 400 µg of rat anti-CD8 or anti-CD4 (rat IgG2b) 
was followed48. Mice were inoculated with CT-26FL3 cells per the hemi-spleen model described 
earlier, followed by T cell depletion on days 4 and 8. In this series of experiments, vaccine 
treatments were administered the same day as tumor implantation, followed by a booster vaccine 
on day 6. pCOMBO traps LCP treatment began on day 4, followed by administrations on days 6 
and 8. The animals were divided into six treatment groups: PBS, pCOMBO traps+ p-AH1-A5 
5’pppdsRNA LCP with anti-CD8, pCOMBO traps+ p-AH1-A5 5’pppdsRNA LCP with anti-CD4, 
p-AH1-A5 5’pppdsRNA LCP, pCOMBO traps LCP, and pCOMBO traps+ p-AH1-A5 
5’pppdsRNA LCP. The treatment regimen, dosing, as well as the bioluminescence analysis of liver 
metastasis burden and quantification corresponding to each treatment on day 6, 9, and 12 is shown 
in Figure 4-6A/B. The effects of the combination therapy on the median survival was further 
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studied. Tumor progression was followed by bioluminescence imaging (Figure 4-6A). Mice were 
euthanized when one of the follow conditions applied: drastic weight gain or loss greater than 10% 
within one week, or clear signs of distress were detected, such as dehydration, inactivity, lethargy.  
It is clear from the results that PBS mice, as well as mice depleted of CD8 T-cells developed large 
metastatic tumor lesions in the liver within the 6-9 days following inoculation (Figure 4-6A).  In 
contrast, mice treated with the single arm treatments, as well as the combination treatment showed 
a significant reduction in liver metastasis burden (3-8 fold) (Figure 4-6B). This reduction in liver 
metastasis burden significantly increased median survival in all treatment groups excluding the 
combination treatment with CD8+ T-cell depletion, compared to PBS (5 days after treatment). 
Ultimately, the combination therapy drastically increased survival by almost 180% in this 
aggressive liver metastasis model (Figure 4-6C). 
4.4.7 Resolving immune suppressive ELS and promoting increased CD8+ T-cell 
proliferation and invasion 
The effect of how changes in the immune profile following the combination treatment 
regimen altered the survival and liver metastasis burden was examined. The treatment regimen, 
dosing, as well as the bioluminescence analysis of liver metastasis burden corresponding to each 
treatment on day 12 is shown in Figure 4-7A. The results clearly show a significant reduction in 
both the single arm treatments of p-AH1-A5 5’pppdsRNA LCP (3 fold) and pCOMBO traps LCP 
(10 fold), as well as in the combination, pCOMBO p-AH1-A5 LCP, arms with CD4 depletion (2 
fold) or void of T-cells depletion (30 fold). Furthermore, the CD8 depletion completely negates 
any therapeutic efficacy, resulting in comparable levels of liver metastasis found in the PBS group. 
The CD4 depleted group results in a reduced therapeutic effect, but still corresponded to a more 
than 2-fold reduction in the liver metastasis burden. Most interestingly, the combination treatment 
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shows a clear increase in the pro-inflammatory activation, in which both the M1/M2 ratio, as well 
as the CD8+ T-cell population are increased (Figure 4-7B). These results confirm the hypothesis, 
in which therapeutic efficacy is dependent on both resolving the immune suppressive 
microenvironment as well as promoting the CD8+ T-cells via vaccination and immune checkpoint 
manipulation. These results clearly demonstrate a therapeutic shift to a pro-inflammatory (anti-
cancer) environment.   
4.4.8 Effects of pTrap LCP and free trap protein on liver, kidney, and blood (toxicity analysis) 
Administration of pTrap LCPs (1 mg/kg QOD x 3) showed no significant changes in the 
population of white blood cell levels compared to PBS mice one or seven days following final 
administration of the pTrap LCPs (Figure 4-8A). However, analysis of mouse whole blood 
samples one day after systemic IV injection of engineered CXCL12 trap protein (1 mg/kg QOD x 
3) resulted in a transient decrease of the white blood cell, lymphocyte, population. A recovery of 
the lymphocyte levels was observed seven days post final injection (Figure 4-8A). The decrease 
in the white blood cell populations is a clear example of the endogenous role CXCL12 plays in 
maintaining/recruiting the immune cells from the bone marrow to the blood and stresses the 
importance of avoiding toxicities through targeted and transient expression of the engineered 
CXCL12 trap via pDNA LCP vector.  
4.5 Discussions and Conclusion 
Here, this dissertation provided the first evidence that an engineered pCXCL12 trap gene 
immunotherapy, expressed transiently and locally in the liver, can drastically resolve the 
establishment of immune suppressive ectopic lymphoid structures. Additional administration of 
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an engineered immune checkpoint blockade, pPD-L1 trap, as well as a robust antigen specific 
vaccine, provides further evidence that increased CD8+ T-cell activation along with reduced the 
immune suppressive tumor microenvironment elicits a promising anti-cancer response. Moreover, 
the ability to manipulate the liver metastasis microenvironment by transfecting hepatocytes with 
engineered traps, allows for future investigation into numerous other factors that may prove to be 
beneficial in modulating the immune response and should be considered in future applications.  
Our liver metastasis cancer model seems to follow a similar phenotype to the HCC model reported 
by Finkin et al. 81. Finkin et al. recently revealed that liver tumorigenesis is promoted by the 
establishment of pro-tumor ELSs associated with chronic NF-κB activation 81. Notably, both the 
liver metastasis model presented in this research and Finkin et al.’s HCC model indicates that ELSs, 
which are commonly present in human liver cancer lesions, aid in tumor development and 
proliferation by promoting a protective immune suppressive microenvironment. These findings 
are distinctly different from the general findings in numerous other cancer types in which the 
establishment of ELSs within the tumor increases the pro-inflammatory and anti-tumor responses 
82-86. It is clear from ours and Finkin et al.’s results that the phenotype of the ELSs established near 
the liver lesions are vastly different compared to tumors in other organs such as the breast, lung, 
colon, and skin. The anti-tumorigenic effect of ELSs found in most non-liver tumor types requires 
a competent adaptive immune system that forms pro-inflammatory ELSs. These ELSs are rich in 
antibody producing B-cells and activated antigen specific CD8+ and CD4+ T-cells 87. Furthermore, 
these anti-tumor ELSs contain a minimal number of immune suppressive cell types such as T-reg, 
MDSCs, and B-reg. However, the ELS phenotype present in the liver lesions of the liver metastasis 
model as well as in clinical liver cancers demonstrates a drastic contrast to the anti-tumorigenic 
ELSs found in most non-liver residing tumors 81. The results clearly indicate that the ELSs formed 
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within the liver consists of numerous immune suppressive cell types. The majority of which are 
MDSCs, T-reg, and B-reg. Although a significant number of CD8+ T-cells and natural killer cells 
were found within the ELSs, the vast number of immune suppressive MDSCs, T-reg, and B-reg 
populations drastically reduces the anti-cancer killing likely due to the high levels of PD-L1 
expression on the surface of these immune cells. Furthermore, the majority of these immune 
suppressive cell types have been shown to provide cytokines, as well as growth and survival factors 
to protect and support the invasion and proliferation of the metastatic niche 88. Interesting, 
understanding the unique structure and the immune cells present in the ELS may explain how the 
adaptive immune system turns from anti-tumorigenic to pro-tumorigenic.  
It is reported that the recruitment of immune cell types to establish the ELSs depends on 
chemoattracting chemokines CXCL12, CXCL13, CCL19, and CCL21 89. However, most of the 
research investigating ELS formation has investigated this mechanism in autoimmune or chronic 
inflammation disease. Although many cancers share several characteristics of diseases based on 
chronic inflammation, it is critical to investigate which critical factors are essential for ELS 
formation in cancers. The ability to deliver genes engineered to express a trap against a specific 
chemokine is a promising tool to help elucidate what other factors, other than CXCL12, are 
essential for the establishment of ELSs in cancer lesions. The establishment of an aggressive 
murine colorectal liver metastasis via hemi-splenic inoculation of colorectal cancer cells allows 
for the investigation of the therapies ability to alter the liver microenvironment and the 
tumor/immune cell profile. Furthermore, the use of this syngeneic model also mirrors the clinical 
cases of the liver metastasis immune environment in which numerous immune cell ELS 
aggregates are established. The findings demonstrate that the pTrap LCP technology provides a 
therapeutic amount of the pCXCL12 trap to the hepatocytes. It is clear from these studies that 
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CXCL12 plays a critical role in the establishment and maintenance of ELSs, in which 
administration of the pCXCL12 trap resolves the establishment of these aggregates. Furthermore, 
following administration of additional immune modulating therapies such as the pPD-L1 trap 
and a cancer antigen specific peptide+adjuvant vaccine increased the pro-inflammatory immune 
response resulting in increased numbers of CD8+ T-cell recruitment to the metastatic niche as 
well as increased M1 macrophage differentiation. Based upon these findings, it is hypothesized 
that the deployment of these pTrap LCPs in patients with liver cancers and established ELSs 
should be explored in clinical trials. Future research should combine this pTrap LCP technology 
which can modulate the livers immune microenvironment with other immunostimulatory agents, 
including immune checkpoint inhibitors or cancer vaccines. Additionally, future application of 
this technology as a treatment for autoimmune or chronic inflammation within the liver, such as 
in cases of hepatitis, may also be explored.  
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Figure 4-1 Formulation, characterization, and liver-specific expression profile of the engineered 
pPD-L1 and pCXCL12 traps  
 
A) pDNA vector map of the pPD-L1 trap first reported by Miao et al. (unpublished), the pCXCL12 trap 
has also been reported by Goodwin et al. and uses the same plasmid backbone B) Transmission electron 
microscopy (TEM) and dynamic light scattering (DLS) analysis of the LCP formulation containing pTraps, 
TEM shows morphology of the LCP core and final LCP. DLS shows hydrodynamic diameter size (~35 nm) 
and surface charge (~10 mV) (zeta potential). C) His (6×)-tag ELISA analysis was conducted to determine 
the organ distribution/expression of the pCXCL12 and pPD-L1 traps in all major LCP-accumulating organs 
and serum as well as the biodistribution of free CXCL12 and PD-L1 protein traps following tail vein 
injections, 1 mg/kg QOD x 3. The liver, serum, spleen, lungs and kidneys were collected on days 1, 2, 4, 
and 8 following final administration of the pTrap LCP or trap protein. Data was expressed as mean ± s.d., 
calculated from samples ran in triplicate and as a concentration relative to the standard His (6x) tag protein 
calibration curve. Scale bar: 50 μm. 
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Figure 4-2 Decreased incidence of colorectal liver metastasis and improved survival via pCOMBO 
Trap LCP treatment  
 
A) Inoculation and treatment schedule/dose as well as bioluminescence signal and tumor burden images on 
day 4, 6, 9, and 12 days post inoculation. Treatment groups included PBS (n=8), pGFP LCP (n=8), combo 
protein traps (n=8), pCXCL12 trap LCP (n=8), pPD-L1 trap LCP (n=8), pCOMBO traps LCP (n=8).  C) 
Tumor burden analysis and quantification (n=8 per group). C) Kaplan-Meier survival curve including all 
treatment groups (n=5 per group).  Survival was determined by evaluating mouse weight, activity, and 
quality of life. Data was expressed as mean ± s.d., calculated from samples. N.S. denotes no significance. 
*, **, or *** denotes p < 0.05, 0.01, or 0.001, respectively, compared to corresponding PBS control and/or 
to nearest significant treatment. Bioluminescence signal scale minimum was set to 1x105 photons/sec to 
increase sensitivity on day 4. Minimum for days 6, 9, and 12 is set to 1x106 photons/sec to reduce 
background signal. 
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Figure 4-3 Improved therapeutic strategy for reducing immune suppressive cells and incidence of 
colorectal cancer liver metastasis via pCOMBO Trap LCP 
 
A) Inoculation and treatment schedule/dose in which mice were inoculated with 1x105 CT-26 FL3 cells 
into one-half of a separated spleen, resection of the inoculated spleen 5 min post inoculation allowed for 
decreased primary tumor burden. Treatment consisted of QOD, days 4-8, administered through tail vein IV 
for pTrap LCP. Treatment groups included PBS (n=3), pGFP (n=3), combo free protein traps (n=3), 
pCXCL12 trap (n=3), pPD-L1 trap LCP (n=3), pCOMBO traps (n=3). Livers were collected from mice, 
analyzed, and quantified the liver metastasis burden via bioluminescence analysis on day 12 B) Liver 
immune cell populations (CD1d+CD138+ ISPC, CD19+ B-Cells, CDllb+GR1+ MDSC, F4/80+CD206+ 
M1/M2, NK1.1+, CD4+, PD-L1+, CD8+) analysis and quantification via flow cytometry (n=3 per group). 
Data was expressed as mean ± s.d., calculated from samples. N.S. denotes no significance. *, **, or *** 
denotes p < 0.05, 0.01, or 0.001, respectively, compared to corresponding PBS control. 
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Figure 4-4 Flow cytometry analysis of immune cell populations (ISPC, B-cells, MDSCs, PDL1-cells, 
CD4, Macrophage (M1/M2), NK, and CD8) within liver metastasis  
 
A) ISPC (CD138+CD1d+), B) B-cells (CD19+), C) MDSC (CDllb+GR-1+), D) PDL1-cells (CD274+) E) 
CD4 (CD4+) F) Macrophage (M1/M2) (F4/80+CD206+/-) G) NK (NK1.1) and H) CD8 (CD8+) immune 
cell populations in metastatic liver environment. 
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Figure 4-5 Biological trapping of endogenous CXCL12+PD-L1 reduces immune suppressive ectopic 
lymphoid structures consisting of numerous aggregated immune cell types  
 
A) Masson trichrome and fluorescently stained paraffin-sections of liver tissues from colorectal liver 
metastasis BALB/c mice sacrificed 12 days after inoculation of tumor cells, including control healthy liver 
with no treatment and void of colorectal cancer (No Liver Mets). Immune-fluorescent stain against CD4, 
FOXP3, GR-1, CDllb, CDld, CD19, CD8, CD45, NK1.1, CXCL12, and PD-L1. All sections had nuclear 
staining with DAPI (blue). All colors are indicated in the top-left of the section image. Three groups were 
studied, including healthy (No Liver Mets), PBS (Metastasis w/ ELS), and pCOMBO Traps LCP 
(Metastasis no ELS). B) Additional sections were stained to determine changes in ELS, CXCL12, and PD-
L1 distribution throughout the liver. Immune-fluorescent stain against ELS (Immune cell aggregates, 
overlapping signal from Immune-fluorescent stains), CXCL12, and PD-L1. All sections had nuclear 
staining with DAPI (blue). All colors are indicated in the top-left of the section image. Five groups were 
studied, including PBS, combo protein traps, pCXCL12 trap LCP, pPD-L1 trap LCP, and pCOMBO Traps 
LCP. The trichrome sections are also shown to distinguish normal liver versus diseased liver metastasis 
morphology and collagen content. Data was expressed as mean ± s.d., calculated from samples ran in 
triplicate. N.S. denotes no significance, N.D. denotes under detection limit, *, **, or *** denotes p < 0.05, 
0.01, or 0.001, respectively, compared to corresponding PBS control. Scale bars: A) 100 µm, B) 500 µm. 
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Figure 4-6 Decreased incidence of colorectal liver metastasis and increased median survival via 
pCOMBO Trap and Vaccine LCP treatment  
 
A) Inoculation and treatment schedule/dose, bioluminescence signal, and tumor burden images 12 days 
post inoculation. Treatment groups included PBS (n=9), pCOMBO traps+p-AH1-A5 LCP+anti-CD8 (n=9), 
pCOMBO traps+p-AH1-A5 LCP+anti-CD4 (n=9), p-AH1-A5 5’pppdsRNA LCP (n=9), pCOMBO traps 
LCP (n=9), pCOMBO traps+p-AH1-A5 LCP (n=9).  B) Tumor burden analysis and quantification (n=9 per 
group). C) Kaplan-Meier survival curve including all treatment groups (n=5 per group).  Survival was 
determined by evaluating mouse weight, activity, and quality of life. Data was expressed as mean ± s.d., 
calculated from samples. N.S. denotes no significance. *, **, or *** denotes p < 0.05, 0.01, or 0.001, 
respectively, compared to corresponding PBS control or to nearest significant treatment. 
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Figure 4-7 Improved therapeutic outcome following increased M1/M2 and CD8+ cell populations 
and reducing immune suppressive ectopic lymphoid structure formation via combination of 
pCOMBO Trap+Vaccine LCP treatment  
 
A) Inoculation and treatment schedule/dose in which mice were inoculated with 1x105 CT-26 FL3 cells 
into one-half of a hemi-spleen. Treatment consisted of QOD, days 4-8, administered through tail vein IV 
for pTrap LCP, days 0 and 6 for SC vaccine, and days 4 and 8 for IP administration of anti-CD8 or anti-
CD4. Treatment groups included PBS (n=4), pCOMBO traps+p-AH1-A5 LCP+anti-CD8 (n=4), pCOMBO 
traps+p-AH1-A5 LCP+anti-CD4 (n=4), p-AH1-A5 5’pppdsRNA LCP (n=4), pCOMBO traps LCP (n=4), 
pCOMBO traps+p-AH1-A5 LCP (n=4). Livers were collected on day 12, analyzed, and quantified for liver 
metastasis burden via bioluminescence analysis B) Liver immune cell populations (M1/M2 and CD8) 
analysis and quantification via flow cytometry (n=4 per group). C) Liver immune cell populations (M1/M2, 
CD8, and MDSC) analysis and quantification via paraffin embedded sections stained via Masson trichrome 
stain, or fluorescent anti-CD8, anti-F4/80, anti-CD206, anti-CDllb, and anti-GR-1 (n=4 per group). Data 
was expressed as mean ± s.d., calculated from samples. N.S. denotes no significance. *, **, or *** denotes 
p < 0.05, 0.01, or 0.001, respectively, compared to corresponding PBS control or to nearest significant 
treatment. 
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Figure 4-8 Toxicological Analysis  
 
A) ALT, AST, creatinine, and BUN enzyme levels, blood cell levels after treatment of PBS, Blank LCP, 
pGFP LCP QOD, free protein traps: CXCL12 trap, PD-L1 trap or both combined, or pDNA LCP 
including pCXCL12, pPD-L1, or both combined pCOMBO LCP 1 mg/kg QOD x 3. Blood samples were 
collected via tail nick at one and seven days following final injection and analyzed for white blood cell 
populations. Mice were euthanized 14 days post final injection and the blood serum was collected and 
analyzed for liver (AST and ALT) and kidney (BUN and Creatinine) biomarkers. All LCP treatments fall 
within normal range. Data was expressed as mean ± s.d., calculated from samples ran in triplicate, *, **, 
or *** denotes p < 0.05, 0.01, or 0.001, respectively, compared to corresponding PBS control. 
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Chapter 5: Summary and Future Studies 
 
5.1 Summary of current work 
In this dissertation, the immune suppressive microenvironment within the liver metastatic niche 
and the current strategies to modulate this microenvironment were discussed extensively. In summary, 
the two approaches for nanoparticle delivery and therapy can be classified into either local or systemic 
immune manipulation. The current strategies focus on both fronts, priming the local tumor and liver 
environment through gene delivery of immunotherapies, while simultaneously priming the hosts 
systemic immune response through a cancer antigen specific vaccine. This approach is particularly 
promising for the treatment of metastatic tumors, propagating in tissue, such as the lungs and liver, in 
which non-viral vectors can accumulate and transfect the healthy cells. Furthermore, through this 
approach Miao et al. demonstrated efficacy in stroma rich tumors, in which the transfection of tumor 
associated fibroblasts (TAFs) which constitute the majority of tumor mass can elicit a therapeutic level 
of local expression. The data presented in this report, firstly, demonstrated that the metastatic lesions 
within the liver are surrounded by immune suppressive cell aggregates. These aggregates generate high 
levels of immune suppressive cytokines as well as high expression levels of PD-L1. This environment 
establishes a metastatic niche resistant to T-cell invasion and killing, ultimately resulting in metastatic 
progression. Therefore, the ability to delivery greater than 50% of the LCPs into the liver, resulting in 
mainly hepatocyte uptake through the asialogycoprotein receptor results in a local, transient, and 
therapeutic level of immunotherapy expression. Therefore, this dissertation focused attention on 
manipulating the local immune suppressive ectopic lymphoid structures in the liver. The pCXCL12 
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trap was utilized as a model therapeutic agent to evaluate this strategy relating to liver immune 
modulation.  
Since the increased secretion of CXCL12 facilitates immune cell recruitment, tumor growth, and 
further CXCL12 secretion through an autocrine mechanism, it was proposed to reduce CXCL12 via 
the in situ generation of a CXCL12 trap. The hepatocytes within the liver are proximal to the metastatic 
lesions and can be utilized to deliver LCPs specifically for therapeutic expression of a gene. Therefore, 
systemic LCP delivery of pDNA encoding an engineered CXCL12 trap was proposed. Indeed, 
CXCL12 trap expression within the liver for up to 4 days following systemic administration was 
observed. Furthermore, reduced CXCL12 levels within the liver was observed in a dose dependent 
manner. This was the first investigation into using healthy cells within a tissue to expression a 
therapeutic engineered antibody-like protein in situ for immune modulation and treatment of a 
metastatic lesion. This approach clearly reduced immune suppressive cell populations within breast 
and colorectal liver metastasis mouse models, as well as prolonged survival through decreasing 
metastatic burden within the liver.  
     However, although the pCXCL12 trap LCP therapy increased survival and significantly 
decreased the immune suppressive microenvironment within the liver, the pro-inflammatory anti-
cancer immune response was deficient due to low levels of CD8+ T-cells within the liver and metastatic 
lesion. Therefore, a more potent combination strategy aimed at transfecting the hepatocytes with 
multiple immunotherapies (pCXCL12 and pPD-L1) as well as priming the hosts systemic immune 
response (LCP cancer vaccine) was investigated. The hypothesis consisted of the pCXCL12 trap, 
reducing the immune suppressive cell populations, the pPD-L1 trap, protecting local effector T-cells, 
and cancer vaccine, increasing cancer specific T-cell activation. The pCXCL12 trap monotherapy 
showed promising therapeutic outcome in both breast and colorectal liver metastatic cancer. Following 
administration of this combination approach, the immune suppressive cell aggregates were almost 
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completely resolved. Furthermore, the metastatic burden in the liver was significantly reduced, 
resulting in over 180% increase in survival. The ability to priming the local liver cells to produce 
therapeutic molecules in situ as well as program the hosts immune cells against cancer specific antigens 
to increase anti-cancer efficacy provides a new paradigm for the treatment of metastatic lesions.         
5.2 Significance and Novelty of the studies 
Overall, the proposed liver and immune cell modulating strategy has the following advantages: 
(1) The high accumulation of LCPs within the liver achieves therapeutic levels of engineered 
immunotherapies with increased anti-cancer efficacy and reduced off-target toxicities. (2) The ability 
to modulate and reduce the immune suppressive cell populations within the metastatic lesion allows 
for future investigation into which factors play a critical role in cancer progression. (3) Local and 
systemic immune modulation resulted in a significant increase in anti-cancer efficacy and survival 
compared to local or systemic immune modulation.  
5.3 Future Expectations 
The ability to engineer healthy cells, surrounding metastatic lesions, to produce therapeutic 
proteins has numerous applications for future exploration. As mentioned in Chapter 1, numerous 
potential targets have been found to play a role in establishing the immune suppressive 
microenvironment within the liver, CXCL1, CXCL5, CXCL12, CCL17, CCL22, MCP-1, VEGF, GM-
CSF, SCF, IL-2, IL-10, TGF-β, IDO, and PD-L1. Therefore, this approach can be used to investigate 
if a reduction in any of the listed factors elicits a therapeutic anti-cancer response. Furthermore, through 
specific reduction of only one factor within the liver, scientist can better understand the mechanism 
and role that the select factor plays in the establishment and progression of the metastatic lesion. An 
alternative approach for future investigation would also be the delivery of immune suppressive 
reducing traps along with an immune stimulating adjuvant. This may be an alternative to facilitate a 
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more robust host specific immune response against the tumor cells compared to a cancer vaccine 
containing only one select cancer antigen. The ability to elicit a robust host immune responses 
generated against numerous antigens presented within the metastatic lesion may reduce the chance of 
tumor immune evasion due to reduced expression of a specific antigen. The success of cancer 
vaccination is strongly hampered by the suppressive tumor microenvironment. Therefore, it is 
hypothesized that this combination approach allows the liver to reduce the immune suppressive 
microenvironment while the immune stimulating adjuvant increase the secretion of Th1/M1 cytokines 
and chemokines, orchestrating cytokine-mediated crosstalk between infiltrating lymphocytes and the 
resident malignant cells, facilitating potent immune response. In this dissertation, the ability to prime 
the liver environment was the focus of study. However, this strategy has potential in other LCP 
accumulating organs, such as the lung and desmoplastic cancers. Besides focusing on hepatocytes, the 
LCP with tunable size, outer leaflet lipids and targeting ligands can be designed to target different cell 
populations within the lung and tumor. This tunable characteristic of the LCP allows this approach to 
be used in numerous other primary and metastatic models to manipulate the immune microenvironment 
and anti-cancer response. 
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